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Chronic wounds are a growing healthcare issue afflicting over 40 million people 
in the United States. Despite the billions of dollars spent each year, complications from 
diabetic ulcers result in a large number of lower extremity amputations. Current dressings 
fail to address the complex nature of the wound environment and are often only able to 
address one aspect of wound healing providing marginal wound closure rates and resulting 
in treatment failure. To address the limitations of standard treatments, we have developed 
a biodegradable and bioactive hydrogel dressing that incorporates a novel antimicrobial 
agent to eliminate and prevent infection. Here, we have developed a wound healing 
platform that promotes wound fluid maintenance through tunable hydrogel geometries, 
targeted cellular interactions, and bacterial inhibition.  
In this work, a tunable biomaterial platform with integrin-mediated cellular 
interactions, controlled degradation profiles, and antimicrobial properties was developed 
to treat a variety of complex wound environments. Engineered Streptococcal collagen-like 
(Scl2) proteins were optimized with improved stability and promotion of cellular 
attachment. These poly(ethylene glycol)-based hydrogels were fabricated in hydrogel 
microspheres and 3D-printed porous hydrogel foams to develop a platform to treat 
complex wound environments. Swelling ratio and rate were investigated to determine 
water uptake and equilibrium swelling times. Furthermore, biocompatibility and 
biodegradation of poly(ethylene glycol)-dithiothreitol hydrogels were modulated and in 




rapid degradation in vivo has potential to be utilized as a resorbable dressing that 
eliminates inflammatory concerns due to residual dressing fragments. Finally, gallium 
maltolate (GaM), a novel antimicrobial agent, was incorporated into these hydrogel 
scaffolds and evaluated in vitro and in vivo in a splinted wound model. Release profiles, 
bacterial inhibition, and wound closure was investigated in these GaM loaded hydrogels. 
Overall, the development of this wound healing platform with conferred 
antimicrobial activity and tunable degradation properties resulted in an improved wound 
dressing system with controlled moisture balance, infection control, and potential for cell 
mediated wound healing. Furthermore, these technologies can be translated into other 
regenerative applications and scaffold geometries demonstrating the broader impacts of 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1.  Clinical Need: Chronic Wounds 
Chronic wounds affect approximately 2.4-4.5 million people in the United States 
and over half of the non-traumatic lower extremity amputations are due to diabetic foot 
ulcers.1, 2 Among those with diabetes, over 85% of amputations are due to foot ulceration.3 
These wounds impose not only a large medical burden but also a financial burden on our 
healthcare system with an estimated cost of $45,000 per patient.2 The current gold 
standard is a multidisciplinary approach focusing on compression, infection maintenance, 
debridement, and appropriate dressing selection.4 Due to the high recurrence rates and 
minimal closure rates, low cost treatments to manage chronic wounds are utilized. 
Unfortunately, these low cost treatments do not provide active wound healing to promote 
cellular migration to the damaged tissue. Current commercially available active wound 
healing options such as Alloderm™, Integra Wound Matrix™, and Dermagraft-TC® have 
concerns and risks relating to infection, potential disease transmission, and high cost.5, 6 
Human skin wounds affect 6.5 million patients per year with an annual financial burden 
of $25 billion in the United States.7 These numbers are expected to rise due to increases 
in the elderly population, obesity, and diabetes.1, 8, 9 The World Health Organization 
estimates that over 350 million people globally are affected by Type I and II diabetes with 
15% of those patients suffering from diabetic foot ulcers.3, 10 It is expected that by 2030, 




chronic wounds are prevalent due to underlying health complications and delayed healing 
times. There have been several advances in wound healing to improve healing capability, 
reduce amputations, and improve patient comfort and care. Recent wound dressing 
research has focused on scaffold design, vascularization, regulatory factors, and accurate 
in vitro models.10 
1.2.  Wound Healing Process 
Wound healing is the biological process of the repair of tissue damage through 
growth and neotissue formation.  There are four main phases in which consist of 
hemostasis, inflammation, proliferation, and remodeling. The wound repair process 
involves several overlapping interactions among cytokines, growth factors, cells, and 
extracellular matrix (ECM) that restores the wounded tissue.11   
1.2.1.  Hemostasis 
The initial phase of wound healing, hemostasis, produces the formation of a clot 
that provides a temporary matrix for cells to attach and migrate through. This clot is made 
up of platelets, crosslinked fibrin, fibronectin, vitronectin, and thrombospondin.12 
Aggregation of platelets that form the clot activate the intrinsic part of the coagulation 
cascade. The formation of the clot initiates the entire healing cascade through the release 
of cytokines and growth factors. The fibrin clot serves as the scaffolding for the invading 
inflammatory and proliferative cells.13 The initial clot plays an important role in the wound 
healing process due to improved cellular interactions at the wound cite and the release of 





1.2.2.  Inflammation 
The inflammatory cells such as neutrophils and macrophages are the first cells to 
arrive at the wound injury which clean out the wound site ridding the wound of bacteria, 
foreign materials, and damaged tissues.16 The inflammatory phase is essential to providing 
chemotaxis of cells through the release of cytokines and growth factors to activate 
migrating cells.17 Neutrophils are the first inflammatory cells to the wound site and are the 
first line of defense to pathogens.17, 18 Next, macrophages invade the wound site secreting 
growth factors that stimulate angiogenesis and fibrous tissue formation as well as 
debridement of surrounding tissue.17, 19-21 
1.2.3.  Proliferation 
As the inflammatory stage leads into the proliferative phase, the fibrin clot is 
remodeled and replaced with ECM to allow for cellular migration and proliferation.11 
Non-activated fibrobalasts become activated so that they can proliferate and provide 
further matrix and wound support.17 In the proliferative phase, fibroblasts and endothelial 
cells proliferate to lay down collagen in order to create a matrix structure and start 
angiogenesis.17 Wound contraction begins aided by the formation of ECM to achieve 
wound closure. The ECM provides a matrix for cells to infiltrate to help return function 
and integrity to the repaired tissue.22 
1.2.4.  Remodeling 
In the final phase of the healing process, remodeling, the collagen fibers become 
crosslinked and remodeled providing strength for wound tissue. Cellular connective tissue 




collagen crosslinking and scar maturation occurs.16 Type III collagen is remodeled into 
type I collagen primarily through the help of matrix metalloproteinases (MMPs) that are 
secreted fibroblasts, macrophages, and endothelial cells which help strengthen the repaired 
tissue.24 
1.2.5.  Chronic Wounds 
Chronic wounds fail to progress through the normal phases of wound healing. In 
chronic wounds, issues with infection, excessive inflammatory responses, biofilm 
development, and the inability of cells to respond appropriately to reparative chemotactic 
factors prevent the normal phases of wound healing from occurring.1, 25 Local and 
systemic factors impact disease states and impact healing. Some local factors include the 
presence of foreign bodies, ischemia and infection while systemic factors include age and 
comorbidities.26 Additionally, reduction of growth factors, proteinase imbalance, and 
senescent cells have been shown to complicate wound healing.27-31 The damage of 
chemotactic factors impairs the proliferative capacities of target cells (keratinocytes, 
endothelial cells, and fibroblasts) that prevent the wound from healing. Due to excess 
inflammation, immune cells produce excess reactive oxygen species (ROS) that damage 
ECM proteins and cause cell damage.1 The harmful effects of microbial infection and the 
control of bacterial balance to prevent wound colonization and biofilm formation has been 
widely investigated.32, 33 Typically, biofilm-related infections fail to be resolved by the 
patients’ immune response due to underlying systemic factors.32 Persistent bacterial 




levels of MMPs and the decreased production of growth factors, thus suggesting that 
chronic wounds develop due to bacteria imbalances.33, 34  
1.3.  Current Wound Healing Options 
Clinical wound dressings are separated into two different approaches: passive and 
active wound healing options. In order to provide the patient with appropriate care an 
assessment of the wound is performed to develop a treatment plan.  The wound 
environment is evaluated on the stage of healing, wound site, wound size, amount of 
exudate, odor, pain, wound edge, and surrounding skin.9 Wound types can vary from deep 
to shallow or necrotic to sloughy. Identification of the wound environment is essential in 
the selection of the appropriate dressing. The intricate environment of these wounds make 
selection of one type of treatment difficult to improve overall wound healing. Clinical and 
experimental evidence has shown that chronic wounds do not follow a progression through 
normal wound healing.35 Ideally, wound dressings would initiate and manage wound 
healing with a focus on the following key design criteria: management of infection and 
wound fluid maintenance, induction of cellular migration and phenotype to promote 
healthy tissue formation, and an appropriate degradation profile. 
1.3.1.  Passive Wound Healing 
Passive wound healing options consist of cotton wool, compression bandages, or 
natural or synthetic gauzes.23 Although these traditional passive wound healing options 
are cost effective they lack the ability to provide cellular cues to initiate the wound healing 
process. Many of these dressings also cause dehydration of the wound bed which is 




because they are so absorbent they cause further tissue damage during dressing changes. 
Modern passive wound dressings such as hydrocolloid dressings, hydrogels, and alginates 
are often applied as gels, foams, or sheets.23 These dressings are good for absorbing wound 
exudate and maintaining a moist wound environment; however, if not applied to clean 
wounds there are concerns with limited oxygen permeability for infected wounds.6 
Hydrocolloid and film dressings are not useful for highly exuding wounds, however; they 
can adhere to both dry and moist wounds. 
1.3.2.  Active Wound Healing 
Commercially available active wound healing skin substitutes range from 
decellularized matrices to bioactive cell derived scaffolds.36 Each of these scaffolds has 
its own unique benefits and disadvantages but common problems exhibited are reduced 
vascularization, biocompatibility, low closure rates, and increased product costs.5, 37-39 
Active wound healing options such as Integra®, Dermagraft®, and OrCel® improve 
wound closure rates; however, there is potential risks of graft rejection due to allogenic 
cells and they do not address infection.40 Bioactive dermal substitutes offer the best closure 
rates but are often expensive since they contain animal-derived extracellular matrix 
(ECM) materials and often cells that require special handling and preparation.37, 39, 41 
Dermagraft®, a bioresorbable mesh, seeded with cryopreserved neonatal fibroblasts, has 
marginal wound closure rates at 30% compared to 18% control group treated with gauze.42  
To improve wound closure rates, research has focused on cellular targeting and signaling 
in order to direct the wound healing process. A summary of clinically available active 




Table 1.1. Current skin substitutes with their identified advantages and disadvantages. 
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1.4.  Hydrogels as Wound Dressings 
Hydrogels are hydrophilic polymer networks that absorb up to a thousand times 
their dry weight in water.43, 44 Many hydrogels exhibit tunable properties that can be 
modulated chemically, physically, and biologically.45-48 Natural polymers (collagen, 
gelatin, alginate, and cellulose), synthetic polymers such as poly(ethylene glycol), and 
hybrid hydrogel systems have all been explored for use in tissue engineering 




applications due to their similar properties to soft tissue, ability to incorporate water 
soluble components, and encapsulate human cells and maintain their viability.52-58  
A primary advantage of hydrogel wound dressings is their ability to influence 
moisture balance in the wound environment.38 Maintaining a moist wound environment 
has been shown to facilitate the wound healing process by preventing tissue dehydration 
and cell death, enhanced angiogenesis, improved breakdown of nectrotic tissue and fibrin, 
and initiating the interaction of chemotactic factors with target cells.59 In order to provide 
the patient with adequate care an assessment of the patient and the wound is done to 
develop a systematic approach for treatment.  In the patient assessment, factors such as 
disease, infection, age, medication, and previous wound management are taken into 
consideration when developing a treatment plan.9 Additionally, the wound is evaluated on 
the following conditions: stage of healing, wound site, wound size, amount of exudate, 
odor, pain, wound edge, and surrounding skin.9 Identification of these issues are important 
in selection of the appropriate dressing. The intricate environment of these wounds make 
selection of one type of treatment difficult to improve overall wound healing.  
Hydrogel wound dressings are clinically applied in three ways: amorphous gels, 
hydrogel sheets, or composite impregnated hydrogels. Amorphous hydrogels are a soft 
formless gel that becomes less viscous as it absorbs fluid. Sheet hydrogels are firm sheets 
that swell with fluid but maintain their mechanical integrity. Unlike alginates or 
hydrocolloids, hydrogels do not require wound secretions to initiate the gel formulation.60 




appropritate primary and secondary dressing selection.60, 61 Many clinically available 




Table 1.2. Comparison of clinically available hydrogel wound dressings adapted from 
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1.4.1.  Hydrogel Degradation 
Hydrogels provide good moisture balance which is a critical wound dressing 
requirement to maintain an appropriate wound environment. Another key requirement is 
the ability for the dressing to degrade as new tissue is regenerated to eliminate 
inflammatory responses due to residual dressing fragments left in the wound bed. Slow 
degrading systems have been shown to reduce nutrient/waste diffusion to cells migrating 
thorough the network, prevent cellular migration thereby reducing tissue ingrowth and 
remodeling, and inhibit the healing process.62-64  
Acrylated and methacrylated poly(ethylene glycol) hydrogels have been shown to 




degradation times.65 Increasing the rate of degradation in PEG-based hydrogels has been 
investigated with the inclusion of PLA; however, it has been shown to denature proteins 
and cause an inflammatory response due to acidic degradation products which would not 
be beneficial for a bioactive wound dressing.63 Additionally, the development of poly(β-
amino ester)s have been investigated as a system to increase hydrolytic degradation.66 
Studies have shown the ability to tune polymer properties such as degradation rate and 
modulus through varying concentrations of PEGDA.67 This system has been widely 
characterized for its tunable mechanical properties; however, with increasing degradation 
rate, there was a significant effect on gel fraction, swelling ratio, and resulting compressive 
and tensile moduli.68-70 
Another proposed chemical modification to increase the rate of degradation in 
PEG-based hydrogels is to incorporate thio-β esters into the polymer backbone. The 
reaction between acrylates and dithoils which occurs rapidly upon mixing creates an easy 
and efficient synthesis. Additionally, these types of step-growth polymerizations can be 
tuned using stoichiometric monomer ratios to get desired endgroup functionality.62, 71 The 
reaction occurs when PEGDA chains react with a dithiol in a Michael-type addition 
reaction to form water soluble PEGDTT polymer chains.72, 73 The increased hydrolytic 
lability of DTT bridges is due to the presence of a thioether bond proximal to ester bond 
present in PEGDA.64, 72 The presence of this thioether creates a more positive atomic 
charge on the carbonyl carbon of the ester, enhancing the reactivity of nucleophilic attack 
which is the first step of a base-catalyzed ester hydrolysis.64 This reaction of DTT with 




properties of the hydrogel as well as degradation rate can be tuned through variations in 
molecular weight of the PEGDA and the DTT concentration.62, 74, 75 Additionally, the 
system can be tuned by incorporating ratios of PEGDTT:PEGDA before crosslinking to 
further tune the degradation rate.67 This biodegradable system has been investigated for 
the use of protein release, 3D stem cell culture arrays, and to examine ECM cell adhesion 
on ligand type and concentration.73, 76, 77  
1.4.2.  Hydrogel Fabrication 
Maintaining a moist wound environment has been shown to improve wound 
healing by preventing tissue dehydration and cell death, accelerated angiogenesis, 
increasing the breakdown of dead tissue, and enhancing the interaction of growth factors 
with target cells.59 The high water content in hydrogels as discussed previously makes 
them ideal for maintaining moist wound environments. The simple fabrication of the 
hydrogel precursor solutions makes them ideal for fabrication of a wide range of scaffold 
geometries with varying properties and applications. Hydrogel scaffold geometries that 
have been utilized include microspheres, porous scaffolds, injectable gel formulations, and 
various molding and patterning techniques.78-85 Recently, 3D-printing of hydrogels has 
been investigated as an enabling technology to generate complex geometries.86, 87 The 
characterization of these scaffold fabrication techniques has demonstrated differences in 
macro- and microstructure, porosity, and mechanical integrity.88 
Hydrogel microspheres have been shown to improve cellular interactions such as 
migration and proliferation.88, 89 Microsphere fabrication gives control over size 




Additionally, microspheres have been used specifically for cell delivery as an injectable 
platform further demonstrating the versatility of this scaffold design.92, 93 The ability to 
deliver hydrogel microspheres via injection allows for adequate space filling of the defect, 
retention of the dressing at the site of injury, and improves ease of application in a clinical 
setting.94, 95 Chitin-based microparticles such as Debrisan™ and Iodosorb™ have been 
used commercially as a wound dressing to promote favorable cell attachment and 
proliferation for enhanced wound healing.96 The use of microparticles in commercial 
dressings demonstrates the utility of these dressings clinically for easy application.  
Porous hydrogel scaffolds have been shown to play a large role in directing tissue 
formation and function.97 Superporous hydrogels have been shown to swell rapidly due 
water uptake via capillary action.98, 99 Superporous hydrogel fabrication has been 
accomplished using a gas foaming technique with pore sizes ranging from 5 to 600 µm.100-
102 These porous structures have supported cellular infiltration and vascular ingrowth in 
vitro and in vivo.103 The use of porous hydrogels could be a potential solution in wound 
environments with heavy wound exudate due their engineered moisture balance control.  
1.5.  Wound Healing Bioactivity 
The extracellular matrix (ECM) is a complex medium consisting of  biochemical 
and biophysical cues such as proteins, growth factors, collagens, laminins, and 
fibronectin.104, 105 In normal phases of wound healing inflammatory and proliferative cells 
release growth factors to begin the active wound healing cascade.106 However; due to high 
levels of matrix metalloproteinases and reactive oxygen species, excessive proteolysis and 




surrounding ECM prevents cellular migration and proliferation resulting in lack of wound 
closure.25 Thus, incorporation of bioactive cues such as proteins and growth factors are 
important for therapeutic treatment of chronic wounds to improve active wound healing.  
1.5.1.  Growth Factors 
Hemostasis is the first phase of the normal wound healing process. This phase 
begins with the formation of a fibrin clot that with surrounding tissue begins to release 
pro-inflmmatory cytokines and growth factors such as transforming growth factor (TGF)-
β, platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and epidermal 




Table 1.3. Growth factor source and primary cell targets. Table adapted from Martin et 
al. 
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These growth factors are polypeptides that control migration, proliferation, and 
differentiation of cells.115 Incorporation of growth factors have been investigated to direct 




Many of these growth factors are chemoattractants and stimulate proliferation of cells 
necessary for wound healing.116 Encapsulation strategies of growth factors has been 
investigated to get controlled release from various synthetic and natural polymers. 
Electrospun meshes and hydrogel scaffolds have been investigated to release multiple 
growth factors to improve skin tissue regeneration through tunable release and improved 
cellular interactions.117-119 Release from these systems is primarily controlled through 
degradation or heparin incorporation encapsulated into hydrogel scaffolds.120-122 
Unfortunately, to be effective in wound healing there must be sustained and prolonged 
exposure of growth factors. Release can be modulated from slow releasing polymer 
networks, however; clinicians will change dressings every 5 to 7 days making this option 
highly expensive. Additionally, it has been shown that the concentration of some growth 
factors needs to be 1000 times more concentrated in vivo than in vitro due to rapid 
diffusion or proteolytic destruction.106 
1.5.2.  Integrin-Mediated Wound Healing 
The extracellular matrix plays a large role in cellular interactions and tissue repair. 
The cell-matrix interactions take place through cell surface receptors, integrins, which are 
composed of two α and β subunits. These integrins have control over adhesion, migration 
and proliferation demonstrating that integrin expression is critical for promoting matrix 
remodeling.17 It has been demonstrated that α1β1 and α2β1 integrins are key players in 
the wound healing process. α1β1 regulates fibroblast proliferation, collagen synthesis, and 
angiogenesis whereas α2β1 increases fibroblast traction and adhesion, and increases 




Table 1.4. Role of integrins in wound healing. *Epithelial cells do not express α1β1. 
 α1β1 α2β1 
Fibroblast/Myofibroblast 
↑ proliferation 
↓ COLL synthesis 
↑ adhesion 
↑ traction 









Imparting bioactivity into synthetic hydrogel scaffolds to mimic the natural ECM 
is typically incorporated through the addition of proteins, peptides, and growth factors. 
Incorporation of these factors have been investigated to direct cell activity and stimulate 
migration and proliferation of fibroblasts and keratinocytes.38 Many chemistries have been 
investigated to successfully tether bioactive molecules into hydrogels to promote and 
target cellular interactions. Acrylation of RGD, collagen, and peptides to allow for 
photopolymerization has been successful utilizing DCC activation and Fmoc protection 
and various amine-NHS chemistries.131-133 Additionally, Michael-type additions, thiol-ene 
and click chemistries, and step-growth derived photoactive macromers have been utilized 
to modulate cell-material interactions using growth factors and peptides.134-138 Although 
peptide-based and mammal-derived proteins have also been investigated as integrin-
targets for use in hydrogel scaffolds, there are concerns with infection and possible disease 
transmission that could further hinder wound healing. Additionally, the reproducibility 






1.5.3.  Designer Collagens 
PEG-based hydrogels have been shown to resist protein adsorption making them 
a blank slate to incorporate specific bioactivity. Streptococcal collagen-like (Scl2) proteins 
can be utilized to impart bioactivity. Scl2 proteins without integrin binding motifs do not 
provide cellular cues for cell adhesion. Scl2 is a unique protein because it forms a stable 
triple helix without hydroxyproline and has advantages over mammalian collagens due to 
the elimination of potential infection or allergic risks.139, 140 Scl2 is also easily modified to 
incorporate different binding sequences and is resistant to non-specific enzyme 
degradation.139 Using site directed mutagenesis specific binding motifs such as GFPGER 





Figure 1.1. Site-directed mutagenesis incorporates specific binding motifs such as 




Wound healing is a dynamic process in which keratinocytes and fibroblasts 
encounter a complex environment with ECM molecules, matrix degrading enzymes, and 




to the extra cellular matrix especially interactions with collagen.25, 143 Most integrins are 
expressed in a wide variety of cells which express several integrins; however, 
investigation into α1β1 and α2β1 have demonstrated to influence wound healing.144 Scl2 
proteins have been shown to promote cellular interactions through α1β1 and α2β1, such 
as an increasing angiogenesis, adhesion, and cellular infiltration in keratinocytes and 
dermal fibroblasts.145 These recombinantly expressed engineered collagen-mimetic 
proteins with GFPGER integrin binding sequences, allow us to target cells vital to the 
wound healing process.146 Keratinocytes and fibroblasts play a significant role in wound 
closure and tissue regeneration and Scl2 proteins have potential to recruit these cells 
through integrin-mediation. Scl2 proteins cannot form stable networks because they are 
not able to form fibrillary structures so they are limited to coatings and soluble protein 
delivery.147, 148 Functionalization of these proteins allows for incorporation into 3D 
scaffolds that will provide a matrix for them to utilized. 
1.6.  Antimicrobials for Wound Healing 
Infection is one of the most common complications with chronic wounds, 
increasing healing times and causing damage to surrounding healthy tissue, exacerbating 
wound damage.23 Despite extensive research on infection control several controversial 
issues still exist: critical wound colonization, the role of biofilm, the role of antimicrobials, 
and the role of antibiotics.149 Colonization of bacteria is due to proliferation without a 






1.6.1.  Silver 
The use of silver is one of the earliest forms of wound care for its use as an 
antiseptic agent.38 Silver has been highly investigated as an antimicrobial because it has 
been shown to be effective against a broad range of micro-organisms.151, 152 Silver is 
absorbed by sensitive strains of bacteria impairing cell walls, inhibiting respiration, and 
inactivating bacterial DNA and RNA.153 Silver is a bactericidal agent that disrupts 
bacterial growth by inhibiting the respiratory chain as well as interfering with electron 
transport, and altering cell membrane permeability. However, it has been suggested that 
uncontrolled use of silver could result in bacteria developing resistance and reported 
incidents of allergic response has occurred.151, 154 One of the main challenges with is 
maintain high enough concentrations for long enough to provide bactericidal effects 
without the development of resistance.152, 155 In order to maintain the effectiveness of 
silver nitrate, it has been demonstrated that twelve applications per day must be used.38 
Additionally, in vitro studies have shown that there have been cytotoxic impacts on 
fibroblasts and keratinocytes which are target cell types in wound healing necessary for 
tissue regeneration.156, 157  
1.6.2.  Iodine and Hypochlorous Acid 
Iodine products are commonly used in wound care to reduce bacterial growth as it 
has been shown to prove effective against most miro-organisms.158 The release of iodine 
in wound dressings has demonstrated the disruption of mature biofilms in vitro.159 
Dressings containg iodine, however; have been contraindicated for patieints suferring 




lactating should not be use these products because iodine can be absobed systemically.161 
Hypochlorous acid is another bactericidal compound that can be used as a broach range 
antimicrobial.162 However it has been shown that this wound care agent could be 
potentially neutralized in the  wound environment reducing its effectiveness.163 Although 
these antimicrobial agents have been sucessful in bacterial inhibiton they have also been 
shown to significantly decrease wound epithelialization. 164 
1.6.3.  Gallium Maltolate 
Gallium maltolate is a coordination complex of gallium and maltol, which has an 
octonal:water partition coefficient of 0.41, illustrating its solubility in both water and 
lipids.165, 166 Gallium maltolate has been found to significantly reduce the number of 
colony forming units (CFUs) of several different bacteria types often causing biofilm 
formation.167-170 Gallium functions as a ferric iron mimic that has been used to control 
various microorganisms by taking advantage of their iron-dependence for growth.171 This 
iron-dependent pathway had demonstrated that there are no issues with bacteria 
developing resistance to GaM as an antimicrobial agent. Literature has shown that 
Staphylococcus aureus has mean inhibitory concentrations (MICs) between 375-2000 
µg/ml which are active against biofilm formation.172 Additionally, GaM has been shown 
that at low doses can provide nearly complete pain relief with topical applications reducing 
inflammation.172, 173 The impact of GaM on cellular actions is unclear but gallium 
promotes collagen synthesis and cell migration, and favorably modulates integrin 





1.7.  Summary and Approach 
Current wound dressings lack a combinatorial approach to address the complex 
factors needed to improve chronic wound healing. The development of a novel hydrogel 
wound dressing platform with tunable degradation, bioactivity, and bacterial resistance 
will provide a system to improve upon the limitations of current dressing options. The 
novel approach of this engineered PEG-based hydrogel platform exhibits tunable 
biodegradation, engineered bioactivity incorporation, versatile scaffold geometries, and 
antibacterial properties. This platform has potential to serve as an ideal wound dressing 
scaffold to promote active wound healing. The incorporation of thio-β esters via the 
reaction between d,l-dithiothreitol (DTT) and poly(ethylene glycol)-diacrylate (PEGDA) 
should accelerate the rate of hydrolysis of PEG-based hydrogels and create for a tunable 
biodegradable system. Investigation of the in vivo degradation rate based on identified 
compositions from in vitro studies will provide a system for identifying hydrogel 
compositions that degrade in clinically relevant time frames. Using a biodegradable 
system, hydrogel wound dressings will be fabricated into different scaffold geometries to 
create a wound dressing platform that can serve to meet the moisture balance requirements 
of different wound environments. Wound healing is a complex process that can be 
approached through a platform system of different scaffold geometries and degradation 
rates to meet specific design requirements necessary for wound moisture balance and 
appropriate cellular interactions (e.g. attachment, spreading, and infiltration). Hydrogel 
scaffolds will be fabricated into injectable microspheres and 3D-printed porous hydrogel 




wound fluid maintenance, promoting cellular infiltration, and maintaining a resorbable 
profile. Furthermore, since these scaffolds will be fabricated using PEG-based hydrogels 
specific bioactivity can be imparted. Engineered Scl2 proteins will be utilized to target 
specific integrins, α1β1 and α2β1, which have been shown to play an important role in the 
wound healing process. Protein stability and effect of functionalization density will 
demonstrate the ability to improve cellular interactions. Finally, the incorporation of GaM 
into hydrogels will be investigated as a means to control bacterial inhibition to provide 
immediate infection control. The innovation of the proposed studies is the investigation in 
vivo degradation of engineered bioactive hydrogel scaffolds with the ability to inhibit 
bacterial growth. Combined, these systems provide fundamental knowledge and tools to 





CHRONIC WOUND DRESSINGS BASED ON COLLAGEN-MIMETIC PROTEINS1 
 
2.1.  Introduction 
Skin wounds can have severe consequences such as amputation and infection risk 
as well as severe quality of life adjustments.2, 7, 35, 176-178 Treatment for skin wounds varies 
depending on the severity of the wound and type of healthcare facility. Skin substitutes 
are often expensive since they contain animal-derived extracellular matrix (ECM) 
materials and often cells that require special handling and preparation.179 Collagen is a 
major component of most skin substitutes due to its structure and bioactive cues.5 
Collagens are abundant extracellular matrix (ECM) proteins, which give structural 
integrity to many tissues and regulate cell functions through interactions with cellular 
receptors and additional ECM constituents. There are at least 28 different mammalian 
collagens, all with a defining left-handed triple helix that is composed of three polypeptide 
chains. Each polypeptide chain contains continuous GXY motifs, where X is often proline 
and Y is usually hydroxyproline.180 Proline hydroxylation and protein glycosylation are 
important in overall triple helix stability and collagen network formation. Unlike many 
commercialized recombinant proteins, the required post-translational modifications of 
collagen have made it difficult to generate viable recombinant collagen products. 
                                                 
1 Part of the data reported in this chapter is reprinted with permission from Advances in Wound Care 
“Chronic wound dressings based on collagen-mimetic proteins,” by Stacy Cereceres, Tyler Touchet, Mary 
Beth Browning, Clayton Smith, Jose Rivera, Magnus Hook, Canaan Whitfield-Cargile, Brooke Russell, and 
Elizabeth Cosgriff-Hernandez, Advances in Wound Care, 2015, Volume 4, Issue 8, pp. 444-456, published 




Synthetic collagen peptides have limited quantities and are cost prohibitive, which has 
limited collagen products to animal sources.181 These animal-derived materials have 
inherent disease risk, batch variability, and are often milled with heterogeneous results.182 
In contrast, bacterial-based collagen mimics have been characterized as triple 
helical proteins despite a lack of hydroxyproline which circumvents the need for post-
translational modifications and enables facile recombinant expression. Several researchers 
are currently investigating these proteins as potentially useful biomaterials.141, 148, 181, 183-
192 Their production and purification from bacterial expression systems allows for batch 
conformity and scale-up.188 One bacterial collagen isolated from Streptococcus pyogenes, 
Scl2, has shown particular promise as a biomaterial for wound care. Scl2 contains an N-
terminal globular domain followed by a collagen-like region composed of GXX repeats, 
where X is often proline or a charged residue to provide helix stability.141,193 Since 
bacterial protein engineering is possible in reasonable timeframes, Scl2 possesses an 
additional advantage in that it can be optimized to possess specific properties.194 Ligands 
for Scl2 have not been identified and therefore selective introduction of mammalian 
collagen sequences can be used to control and tune cell-material interactions. This is a 
feature unavailable with current animal collagens which offer a broad array of signals to 
cells. We previously used site directed mutagenesis to introduce the GFPGER motif into 
the Scl2 sequence (termed Scl2GFPGER) and provided evidence that human integrin binding 
sites function within Scl2GFPGER to bind and activate α1β1 and α2β1. Integrins are cell 
surface heterodimers that enable outside in and inside out signaling which regulate 




processes in wound healing.130, 194-204 The Scl2GFPGER platform provides a unique 
opportunity to investigate the contribution of collagen binding integrins to wound healing. 
Although integrin signaling is not the only event leading to wound closure, our scouting 
studies in a rodent excisional model demonstrated that soluble Scl2GFPGER application 
increased wound closure rates. Since soluble protein is not a therapeutically viable option, 
we have incorporated the Scl2GFPGER into microspheres that should retain the same 
bioactivity. 
The collagen-mimetic protein, Scl2GFPGER, was incorporated into hydrogels 
utilizing conjugation chemistry developed in our lab to generate a robust wound 
dressing.148 Specifically, the Lys residues of Scl2GFPGER were conjugated to a photo-
crosslinkable poly(ethylene glycol) (PEG) linker for incorporation into the hydrogels. We 
have previously demonstrated that the degree of functionalization has an effect on cell-
material interactions where a higher degree of functionalization imparted steric hindrance 
of the integrin binding site.205 Sufficient functionalization is required to anchor proteins 
within the hydrogel and too little functionalization results in protein loss and reduction of 
cell adhesion. Here, we present a redesigned Scl2 backbone to address these issues, 
Engineered Collagen (eColGFPGER). The eColGFPGER was designed to have 
functionalization sites further away from the integrin-binding motif to decrease steric 
hindrance.  
Although hydrogel dressings are common in wound care management, slabs or 
sheets of hydrogels may be difficult to fit to deep or irregularly shaped wounds. Cellular 




degradation. In contrast, hydrogel microspheres provide a gel-like dressing that is able to 
conform to wound shape offering immediate hydration balance and infection protection 
to the wound. Cellular infiltration into the microsphere network is facilitated by the gaps 
between each particle. Moisture control is also expected to be enhanced due to the 
increased surface area allowing for more rapid water uptake and diffusion. Typical 
fabrication of hydrogel microspheres involving water-in-oil emulsions; however, these 
methods suffer from size heterogeneity and decreased yields.206 Droplet formation using 
passive co-flowing streams can provide greater control over droplet size and uniformity.207 
Fluidic methods have shown improved fabrication processes with the potential to 
photopolymerize hydrogel microspheres.208  
In this study, integrin affinity and cell adhesion to Scl2GFPGER, eColGFPGER, or an 
animal-derived collagen control were determined as an initial assessment of potential for 
wound care applications. Two microsphere fabrication systems were investigated to 
fabricate monodisperse hydrogel microspheres or to increase fabrication throughput 
achieving smaller average particle sizes for injectable delivery. Finally, hydrogel 
microspheres were fabricated using a co-fluidics setup and the water uptake properties of 
both hydrogel slabs and microspheres were quantified. The potential of this dressing to 
conform to an irregular wound was then demonstrated in a rat model. Overall, this strategy 
harnesses biological dressing advantages while providing wound coverage and hydration 






2.2.  Materials and Methods 
2.2.1.  Materials 
All chemicals were purchased from Sigma Aldrich (Milwaukee, WI) and used as 
received unless otherwise noted. 
2.2.2.  Protein Engineering 
Recombinant eColGFPGER protein was derived from Scl2 containing integrin-
binding motif GFPGER at positions 118-123. The C-terminus of Scl2 contains regions 
where triple helix is predicted to be less stable and contributes to a lower melting 
temperature (algorithm used to predict collagen stability is described in Persikov et al.193). 
Using this algorithm GXY triplets were identified that may contribute to protein stability 
and selected triplets were mutated to more stable triplets. To generate a more thermally 
stable collagen, two triplets GKDGKD were mutated to GDRGER (Lys314→Asp314, 
Asp315 →Arg315, Lys317→Glu317, Asp318→ Arg318) where D and E at X position 
and R in Y position of GXY triplet are predicted to be more stable and are more frequent 
in eukaryotic collagens. To stabilize functionalization of Scl2GFPGER single Lys residues 
were replaced by Arg residues in GKD triplets at Lys positions 182, 236, 248, 263, 269, 
275, 278, 284, 290, 293, 299, 305, 308, and 323 (the Arg at the X position of a GXY triplet 
exist at same frequency in eukaryotic collagens as replaced Lys residues and are similarly 
thermally stable). The mutations were introduced by gene synthesis (Genewiz). Histidine-
tagged recombinant proteins were expressed from a pCold vector in E. coli Top3 cells and 
purified by Ni++ affinity chromatography on a 5 ml column (GE Healthcare). Protein 




blot analysis. SDS-PAGE analysis was used to determine multimer formation as 
described. Briefly, proteins were denatured by incubation at 95°C for 5 minutes in the 
presence of 0.1% SDS and 2% β-mercaptoethanol. Non-denatured samples were 
incubated in 5% glycerol and kept on ice prior to electrophoresis on 12% SDS gels. Gels 
were stained with Coomassie blue, and protein migration as it corresponds to size was 
determined using protein standard. 
2.2.3.  Circular Dichroism 
Circular dichroism spectra of protein samples in 50 mM Acetic acid were recorded 
on a Jasco J720 spectropolarimeter in a thermostatically controlled cuvette with a 0.5 mm 
path length. Data were collected at ambient temperature in a wavelength range from 250 
nm to 190 nm, and integrated for 1 s at 0.2 nm intervals with a bandwidth of 1 nm. For 
each spectrum, ten scans were averaged and the contribution from the buffer was 
subtracted. For thermal transition experiments, the ellipticity at 220 nm in a cuvette with 
a 0.5-mm path length was monitored as the sample temperature was increased from 25 to 
50°C, with an average temperature slope of 10°C/h. 
2.2.4.  Protein Functionalization 
Scl2GFPGER, eColGFPGER, and rat tail collagen type I were functionalized with Aam-
PEG-I. Briefly, Aam-PEG-I was dissolved in anhydrous dimethylformamide and added 
dropwise to a collagen solution in phosphate buffered saline (PBS) and Scl2GFPGER and 
eColGFPGER in 50 mM acetic acid at room temperature (acetic acid for Scl2GFPGER and 
eColGFPGER). The molar ratio of Aam-PEG-I:NH2 was 0.1:1 for collagen and Scl2GFPGER, 




= 20,000 Da) was used to purify functionalized proteins. FTIR spectroscopy confirmed 
functionalization of proteins with Aam-PEG-I. 
2.2.5.  Solid Phase Binding Assays 
Microtiter wells were coated with 2 µg per well of recombinant alpha 1 integrin I-
domain. The samples were blocked with TBS containing 2% bovine serum albumin (BSA) 
for 1 hr. Solutions of 1 µM Scl2GFPGER, eColGFPGER, functionalized Scl2GFPGER or 
functionalized eColGFPGER were added to the wells and incubated for 1 hr at room 
temperature. Rabbit polyclonal antibodies raised against Scl2GFPGER followed by donkey 
anti-rabbit-HRP and SigmaFast OPD were used to detect bound proteins. The absorbance 
at 450 nm was measured using a Thermomax plate reader. 
2.2.6.  Cell Adhesion Study 
All cell culture supplies were purchased from Life Technologies (Carlsbad, CA) 
and used as received unless otherwise noted. To assess adhesion and spreading of HT1080 
fibroblasts, 48 well tissue culture polystyrene (TCPS) plates were coated with 10 μg of 
Scl2GFPGER, eColGFPGER, rat tail collagen type I or Scl2 overnight at 4°C. Protein solutions 
(0.1 mg ml-1 20 mM acetic acid) were filtered through 0.22 μm PVDF syringe filters prior 
to coating (4 wells per protein type). Wells were blocked with 4 vol% BSA in PBS for 1 
hr at room temperature and rinsed with sterile PBS three times. HT1080s were cultured in 
DMEM with 10% fetal bovine serum and 1% penicillin-streptomycin. Cells were adapted 
to serum-free media for 12 hr prior to seeding at 5,000 cells cm-1 in protein-coated TCPS 
well plates. After 3 hr of exposure, wells were rinsed three times with warm PBS to 




20 min at room temperature. Cells were stained with rhodamine phalloidin 
(actin/cytoplasm, Sigma-Aldrich) and SybrGreen (DNA/nucleus) and imaged (3 images 
per sample, 4 samples per protein) on a DeltaVision Elite microscope (GE Healthcare). 
Fluorescent images of SybrGreen- and rhodamine phallodin-stained cells were utilized to 
quantify cell adhesion and spreading. Manual counts of SybrGreen-stained cell nuclei in 
each image provided adhesion density measurements. Spreading, or cell area, was 
quantified by applying the Photoshop “magic wand” tool to image backgrounds until all 
extracellular regions were selected. The histogram function was utilized to determine the 
number of extracellular pixels (PEX), and the average number of pixels per cell (ACELL) for 
a given image was quantified as: 




where PT is total image pixels and N is total number of cell nuclei. Pixels were then 
converted to microns using known objective scaling. 
2.2.7.  Synthesis of Poly(ethylene glycol) diacrylate (PEGDA) 
PEGDA was synthesized according to a method adapted from Hahn, et al.56 
Briefly, acryloyl chloride was added dropwise to a solution of PEG 2 kDa or 6 kDa diol 
and triethylamine in dichloromethane (DCM) under nitrogen. The molar ratio of PEG, 
acryloyl chloride, and triethylamine was 1:2:4, respectively. After the addition of acryloyl 
chloride, the reaction was stirred for an additional 24 hours at room temperature. The 
resulting solution was then washed with 8 molar equivalents of 2 M potassium bicarbonate 
to remove acidic byproducts. The product was then precipitated in cold diethyl ether, 




2.2.8.  Synthesis of Poly(ethylene glycol) diacrylate with thio-β esters (PEGDTT) 
PEGDTT was synthesized by adding d,l-dithiolthreitol (DTT) and triethylamine 
(TEA) dropwise to a solution of PEGDA (2 kDa) in DCM. The molar ratio of DTT, PEG 
and triethylamine was 2:3:0.9, respectively. After the addition of the DTT and 
triethylamine, the reaction was stirred for 24 hours at room temperature. The resulting 
solution was then precipitated in cold diethyl ether, washed, filtered, dried under ambient 
conditions for 24 hours then placed under vacuum to remove any excess solvent.  
Characterization of PEGDA and PEGDTT was confirmed using Fourier transform 
infrared spectra (FTIR) and proton nuclear magnetic resonance (1H-NMR) spectroscopy. 
Transmission FTIR spectra of control and functionalized polymers were acquired on a 
Bruker ALPHA spectrometer by solution casting directly onto KBr pellets with 32 scans 
and a resolution of 2 cm-1. Proton NMR spectra of control and functionalized polymers 
were recorded on a Mercury 300 MHz spectrometer using a TMS/solvent signal as an 
internal reference. Percent conversions of PEG diol to acrylate endgroups was greater than 
85%. 1H-NMR (CDCl3): δ 3.6 ppm (m, -OCH2CH2), 5.8 ppm (dd, -CH=CH2), 6.1 
(dd, -CH=CH2) and 6.4 ppm (dd, -CH=CH2). PEGDTT number average molecular weight 
(Mn) was determined by normalizing to the PEG backbone and calculating the number of 
DTT macromers bound to PEG.  
2.2.9.  Hydrogel Characterization 
Hydrogels were fabricated by making (10 wt%) precursor solutions in RO water 
to demonstrate a tunable degradation rate. A photoinitiator solution (1 mg Irgacure 2959 




pipetted between 1.5 mm spaced plates and crosslinked by 6 min exposure to long wave 
UV light (Intelli Ray Shuttered UV Flood Light, Integrated Dispensing Solutions, Inc., 
365 nm, 4 mW/cm2). To measure water uptake, eight 8-mm discs were punched from 
hydrogel sheets. Samples were swollen in RO water for 24 hours and weighed to determine 
the equilibrium swelling mass (Ws). Then specimens were dried under vacuum overnight 
to determine dry mass (Wd). The equilibrium swelling ratio (Q) was calculated from the 










2.2.10. Hydrogel Microsphere Co-flow Fluidics Fabrication 
A 30% hydrogel precursor solution was prepared by dissolving PEGDA (6 kDa) 
in water. The solution was mixed, and a photoinitator solution (1 mg Irgacure 2950 per 10 
µL 70% ethanol) was added at 1 vol % of precursor solution. Microspheres were then 
fabricated via a fluidics water in oil emulsion technique adapted from Gokmen et al.209 
The hydrogel precursor solution was injected dropwise (KD Scientific-100 Infusion 
Pump) into an external mineral oil phase (Harvard PHD 2000 Infusion Pump) and passed 
through UV excitation (UVP High Performance Transilluminator 365 nm) for 2 min to 
initiate radical crosslinking. Needle gauge, aqueous flow rate, and hydrogel injection rate 
were varied to modulate particle size. Collected microspheres were filtered using vacuum 




Optical) with 3.0 mega pixel built in camera using Motic Image Plus 2.0. A total of 10 
particles were analyzed for 4 different batches (n =40). 
2.2.11. Bulk Microsphere Fabrication 
To increase fabrication throughput, a bulk microsphere technique was established 
and variables were modulated to control average particle size. A 20% hydrogel precursor 
solution was prepared by dissolving a ratio of 75% PEGDTT to 25% PEGDA (6 kDa) in 
water. The solution was mixed, and a photoinitator solution (1 mg Irgacure 2950 per 10 
µL 70% ethanol) was added at 3 vol% of precursor solution. The external continuous 
phase consisted of light mineral oil, oil soluble photointiator, and a surfactant. An oil 
soluble initiator, phenylbis(2,4,6-trimethylbenzoyl)phospine oxide, solution (15% w/v in 
acetone) was added at 1-10 μL/ml of mineral oil. The surfactant, polyglycerol 
polyricenoleate (PGPR 4125 – donated by Palsgaard), was added at 1-10 wt% of the 
mineral oil. Microspheres were then fabricated via water in oil emulsion technique using 
a FlackTek Speedmixer DAC 150 FVZ-K. The external continuous phase was mixed at 
100 rpm for 2.5 minutes prior to emulsification. Once, thoroughly mixed, the hydrogel 
precursor solution was added in one addition (1 ml precursor solution per 6 ml mineral 
oil) and mixed between 750-2000 rpm for 5 minutes. The emulsion was then transferred 
to petri dishes and exposed to UV light (UVP High Performance Transilluminator 365 
nm) for 12 minutes to initiate radical crosslinking. Collected microspheres were then 
filtered and purified through a series of ethanol ramps and vacuum aspiration. Hydrated 




Bulk microparticles were imaged using a 10X objective with phase contrast on a 
Motic AE3 using a Moticam 1SP 1.0 MP camera connected to the microscope with Motic 
Image Plus 3.0. Particle size was then determined utilizing Motic Images Plus 3.0 software 
scale and measurement tools. A total of 10 particles were analyzed for 4 different batches 
(n =40). Lyophilized hydrogel microspheres were rehydrated in 1.5 mL of PBS in two 
solution mixes. First, 750 µL of PBS was drawn into the syringes using a 16G needed and 
mixed 10 times by drawing the plunger up and down. After 2 minutes of rehydration, the 
remaining 750 µL of PBS was drawn into the syringes and the same procedure for mixing 
was followed. After full hydration of hydrogel microspheres delivery was investigated 
through controlled injection volumes. 
2.2.12. Rat Excisional Wound Model 
A 3 month old male Sprague Dawley rat that had been euthanized less than an hour 
previously was obtained through the Comparative Medicine Program at Texas A&M 
University. This was done under AUP IACUC 2014-010 “Maintenance & Utilization of 
Animals for Animal Care & Use Training” which allows for excess animals and animals 
euthanized under other AUP’s to be utilized in a tissue share program to maximize use of 
all research animals. A ~1.5 x 2.0 cm full-thickness irregularly shaped defect was created 
on the dorso-lateral aspect of the rat and extended into the underlying muscle layers.  
2.2.13. Statistical Analysis 
All statistical analyses were expressed as the mean ± standard derivation of the 
mean. Statistical analysis was performed by an unpaired two-tailed student’s t-test. 




2.3.  Results and Discussion 
2.3.1.  Protein Engineering 
First, we modified the Scl2 protein to enhance its use as bioactive component of 
our hydrogel wound dressing. Efforts were taken to improve Scl2GFPGER’s thermal stability 
and reduce steric hindrance of the PEG linkers around the integrin binding site. 14 single 
Lys in the collagen-like region of the protein were mutated to Arg residues in GKD 
triplets, which was predicted to have similar thermal stability, but not support PEG-linker 
attachment. The resulting protein, eColGFPGER, was then evaluated for retention of a triple 
helix, thermal stability, and integrin interactions. After recombinant production and 
purification of eColGFPGER, circular dichroism was used to assess the protein’s triple helix. 
Figure 2.1A and 2.1B, showed a typical triple helical spectra with a peak at 220 nm 
indicating our protein engineering did not disrupt the triple helix. In addition, SDS-PAGE 
analysis revealed the presence of multimers (data not shown). A marked increase in 









Figure 2.1. CD analysis indicates that functionalization does not significantly affect 
triple helix formation. CD wavelength scans of (A) Scl2GFPGER (black) and F-Scl2GFPGER 
(red) and (B) eColGFPGER (black) and F-eColGFPGER (red) demonstrate the presence of a 
peak at 220 nm, indicative of a triple helical structure. CD thermal transition of (C) 





The collagen-mimetic proteins were then functionalized with PEG linkers to 
determine whether eColGFPGER had improved integrin binding site availability. FTIR 
spectroscopy was first used to confirm successful functionalization of Scl2GFPGER and 
eColGFPGER with PEG linkers to formulate F- Scl2GFPGER and F-eColGFPGER, respectively. 
The functionalized protein spectra contained absorption peaks corresponding to the 
carbonyl of the amides (~1650 cm-1) in the protein backbone and ether (~1110 cm-1) of 




effect of protein functionalization on recombinant α1 I-domain binding. We consistently 
observed a decreased in integrin affinity regardless of which collagen-mimetic was 
analyzed; however, the observed decreased was less pronounced with eColGFPGER, Figure 
2.2. Protein binding was measured using polyclonal antibodies raised against Scl2GFPGER 
in rabbits; however, these polyclonal antibodies displayed similar titers against all 





Figure 2.2. eColGFPGER exhibits reduced steric hindrance of PEG linkers. 1 μM collagen-
mimetic, Scl2GFPGER, F-Scl2GFPGER, eColGFPGER, and F-eColGFPGER, were incubated with 
immobilized recombinant human α1 I-domains (1 μg/well) with 1 mM Mg2+. Collagen-
mimetic binding was detected as described in Experimental Procedures. Data shown are 
representative of at least three replicates and normalized to the nonfunctionalized control 




The Scl2 backbone has been characterized as a potentially useful recombinant 
biomaterial and can support the introduction of human integrin sequences to facilitate cell 
adhesion, migration, and proliferation.141, 148, 181, 184-188, 190-192, 194, 210 Our results 
demonstrate that selective triplet substitutions may be used to further optimize the 
backbone helix to achieve certain properties. Given that it has been established that a triple 
helical conformation is required for integrin binding and activation197, 198, 200, 211, our 
demonstrated ability to stabilize triple helices is expected to affect ligand interactions and 
potentially cellular behavior.124 To anchor these proteins into the hydrogel, it is necessary 
to first functionalize the protein with PEG linkers that can photocrosslink with the PEG 
matrix. The placement of these PEG-linkers along the triple helical backbone can have 
significant implications regarding integrin binding site availability to cells due to steric 
hindrance.205 Our targeted modification of the Scl2 protein to limit the steric hindrance of 
these PEG linkers during integrin binding was successful. In addition, stability predictions 
were used to mitigate any changes in the backbone that might result in disrupted interchain 
interactions. These efforts resulted in a protein construct with an increase in melting 
temperature of ~7°C. The studies here show an increase in cell adhesion on eColGFPGER 
compared to Scl2GFPGER indicating that these substitutions had some effect on cell-material 
interactions.  
2.3.2.  Cell-Material Interactions 
To assess the functionality of the integrin binding site in eColGFPGER, HT1080 
fibroblast adhesion and spreading on protein coats was assessed at 3 hours, Figure 2.3. 




significant increase in adhesion was observed on Scl2GFPGER with the introduction of the 
integrin binding site into Scl2, as shown previously.148 A further increase in adhesion was 






Figure 2.3. HT1080 fibroblast adhesion and spreading on collagen-mimetic 
protein-coated wells. (A) Adhesion numbers on protein coats after a 3-h incubation 
period. (B) Average cell spreading (area) at 3 h. (C) Rhodamine phalloidin and SYBR 
Green-stained HT1080 fibroblasts. n=4 wells per protein, 3 images per well for a total of 
12 images per sample; mean±standard deviation displayed; °‡* indicate statistically 





Analysis of HT1080 fibroblast interactions demonstrated that eColGFPGER induced 
comparable cell adhesion to that of collagen I. Considering the presence of only one 




sites, this result demonstrates a notable increase in protein functionality. Furthermore, 
when compared with Scl2GFPGER, significantly higher cell adhesion was induced on 
eColGFPGER. These two proteins have the same integrin binding motif; thus, the increased 
integrin interactions with eColGFPGER are either due to its increased thermal stability or an 
overall triple helical change resulting in altered integrin interactions. A stable triple helix 
is required for integrin α1β1 and α2β1 binding to the GFPGER site. Cells were incubated 
on protein-coated plates at 37°C, which is the approximate melting temperature of both 
collagen I and Scl2GFPGER.
212 Therefore, it is possible that both collagen and Scl2GFPGER 
experienced some denaturation during this experiment, rendering their integrin binding 
sites inactive. eColGFPGER was well below its thermal transition temperature of ~45°C in 
this experiment, indicating that it was intact with active integrin binding sites. However, 
we cannot rule out the possibility that these changes did not have an effect on the 
interaction with the integrin itself and studies are underway to characterize the binding 
mechanism. 
2.3.3.  Hydrogel Characterization 
The final purified polymer structure of PEGDA and PEGDTT was confirmed with 
both FTIR and 1H-NMR spectroscopy. For PEGDA, the presence of ester peaks at 1730 
cm-1 and loss of hydroxyl peaks at 3300 cm-1 in the IR spectra confirmed successful 
acrylation. For PEGDTT, the loss of the thiol stretch at 2600 cm-1, the presence of the 
hydroxyl peaks at 3300 cm-1 and decrease in the 842 cm-1 peak correlating to the carbon 
carbon double bond confirmed successful coupling, Figure 2.4. The ratio of integrated 




structure of PEGDA. Percent conversions of PEG-diol to acrylate endgroups was greater 
than 90%. The PEGDTT structure and number average molecular weight (Mn) was 
determined by the ratio protons of the methyl groups in the PEGDA backbone to the 
number of protons from DTT backbone. The Mn was found to be 6.4 kDa with an 





Figure 2.4. Transmission FTIR spectrum of the PEGDTT (Top), PEG(2k)DA (Middle), 
and DTT (Bottom). Transmission FTIR spectra of control and functionalized polymer 
neat films were acquired on a Bruker ALPHA spectrometer by solution casting directly 









Figure 2.5. H1NMR spectra of the PEGDTT in CDCl3. Proton NMR spectra of control 
and functionalized polymer solutions were recorded on a Mercury 300 MHz 
spectrometer using a TMS/solvent signal as an internal reference. 1H NMR (CDCl3): δ 
3.6 ppm (m, -OCH2CH2), 5.8 ppm (dd, CH=CH2), 6.1 (dd, CH=CH2), and 6.4 ppm (dd, 




Finally, its fabrication into hydrogel microspheres provides a bioactive dressing 
that can readily conform to irregular wounds. Future studies will determine if the observed 
enhancement in cell interaction is conferred to the bioactive gels and due to reduced steric 
hindrance around the integrin binding site, increased stability of the triple helix, or a 
combinatory effect. Overall, this new eColGFPGER shows strong promise in the generation 
of bioactive hydrogels for wound healing as well as a variety of tissue scaffolds. 
2.3.4.  Hydrogel Microsphere Properties 
Microspheres fabricated using the water-in-oil emulsion technique described 
above were filtered using vacuum aspiration and then characterized, Figure 2.6. Fully 
swollen fabricated microspheres had an average diameter of 878 ± 45 µm. Particles of this 




hydrogel phase flow rate, and 1.6 mm inner diameter PVC tubing (McMaster-Carr). A 
blunted 30-gauge needle was used to inject the hydrogel precursor solution into the 
continuous mineral oil phase. Particle size can be tuned by changing the flow rates of the 
continuous and dispersed phases. Decreasing the flow rate of the continuous phase or 
increasing the flow rate of the dispersed phase decreases the particle size. The flow rate 
of the continuous phase has the most impact on particle size and shape.  
 
Figure 2.6. Schematic of microsphere fabrication. Using co-flow fluidics, hydrogel 
microspheres were fabricated by injecting dropwise a hydrogel precursor solution into a 
continuous mineral oil phase, creating a water-in-oil emulsion. Hydrogel microspheres 
were then cross-linked using UV light while traveling along the tubing. Reprinted from 






Swelling ratio and water uptake of 10% PEGDA (6 kDa) and PEGDTT (5.8 kDa) 
hydrogel slabs were measured to compare to 30% PEGDA (6 kDa) microspheres, Table 
2.1. Both the 1.0 PEGDTT and PEGDA hydrogel slabs had similar swelling and water 
uptake values. The microspheres had a slightly lower but comparable swelling ratio and 
water uptake values compared to the hydrogel slabs which demonstrate the ability of the 
hydrogel microspheres to absorb wound exudate. Finally, we demonstrated that this 
tunable microsphere design allows for improved wound filling when applied to irregularly 
shaped wounds in a rat model, Figure 2.7. The defect was packed with hydrated 





Table 2.1. Swelling and water uptake comparisons of PEGDTT and PEGDA slabs and 
microspheres. a,bIndicate statistically significant differences between respective samples 
p<0.05. PEGDA, poly(ethylene glycol) diacrylate; PEGDTT, poly(ethylene glycol) d,l-
dithiothreitol. Reprinted from Cereceres et al.67 
 
Swelling Ratio (Q) 
Water Uptake  
(mL H2O / g polymer) 
PEGDTT Slaba 15.31 ± 0.49 14.32 ± 0.49 
PEGDA Slabb 16.41 ± 0.94 15.41 ± 0.94 








Figure 2.7. Hydrogel microspheres filling the wound defect in rat model. (A) Irregularly 
shaped wound on the dorsolateral aspect of the rat (B) Wound packed with hydrated 
microspheres, 5 mm scale bar (C) Swollen hydrogel microspheres, 1 mm scale bar. 




Although the fabrication of these co-fluidic hydrogel microspheres resulted in 
uniform particle size, batch size and throughput was limited by the fabrication technique. 
Additionally, co-flow microsphere sizes were tuned between 499.6 ± 84.9 µm and 1064.9 
± 42.5 µm based on external oil flow rate of 600 µL/min and 2000 µL/min, respectively. 
To further decrease particle size an external flow rate of 3000 µL/min was used, however; 
there was no statistical difference in particle size at the 2000 uL/min flow rate. Although 
it was demonstrated that particle size could be tuned using this system we were limited to 
sizes 500 µm and above. To address these limitations, we investigated the use of a 
FlackTek Speedmixer to improve up-scale techniques and fabrication time utilizing an oil-








Figure 2.8. Schematic of bulk microsphere fabrication. Using emulsion fluidics, 
hydrogel microspheres were fabricated by creating a water-in-oil emulsion. Hydrogel 




Average particle size was tuned through control of emulsion fluidic parameters 
such as mixing speed, surfactant concentration, and concentration and use of a dual 
initiator system, Figure 2.9. Modulation of mixing speeds resulted in average particle 
sizes between 30 ± 14 µm and 94 ± 78 µm with smaller particle sizes observed at higher 
mixing speeds due. Additionally, concentration of surfactant was investigated to modulate 
average particle size with average particle sizes ranging from 40 to 70 µm. Franco et al. 
demonstrated the use of a dual-photoinitiator technique to improve microparticle yield and 
crosslinking at the surface.206 To further modulate our system, an oil soluble and water 
soluble initiator were used to investigate effect on particle size ranging between 30-70 µm. 
Another limitation of the co-fluidics system was the inability to make smaller particle size 
despite modulation of system parameters but we demonstrate the ability to tune particle 
size with this bulk system between 95 and 30 µm through controlled emulsion variables. 
Although this system did not result in uniform particle size distribution, the delivery and 
space-filling capability of this system was maintained, Figure 2.10A. Additionally, the 




technique, Figure 2.10B. After lyophilization and rehydration of the microspheres in a 
syringe, controlled injections of 100 µL were weighed to determine delivery 
reproducibility. Five injections per syringe were analyzed with an average delivery of 
78.68 ± 4.05 mg demonstrating delivery of controlled doses. This injectable delivery 
system can reproducibly and accurately deliver a targeted dose of microspheres. This 
important fabrication modification, demonstrates the capability to incorporate therapeutic 
agents into these hydrogel microspheres for controlled delivery of proteins or 








Figure 2.9. Average microsphere particle size was tuned through controlled emulsion 
parameters to create a tunable system for injectable delivery. Scale bar represents 50 µm 








Figure 2.10. A) Wound packed with hydrated microspheres demonstrating space-filling 
capability. B) Microsphere rehydration and delivery protocol developed to accurately 




2.4.  Conclusions 
Although hydrogel sheets are popular wound dressings, these passive dressings do 
not promote regeneration, require frequent changing, and cannot conform to irregularly 
shaped wounds. Previously, we fabricated bioactive hydrogels through the addition of 
collagen-mimetic proteins that can regulate key processes in wound healing. Here, we 
present a novel collagen-mimetic protein with reduced steric hindrance, reduced melting 
properties, and increased cell-material interactions. A collagen mimetic, eColGFPGER, was 
developed that has improved stability and functionalization profile while maintaining 




controlled modulation of degradation rate without impact on other physical properties. 
Hydrogel microspheres were then fabricated to provide a dressing that can readily conform 
to irregular wounds and facilitate cell infiltration. Finally, the microsphere fabrication 






CHAPTER III  
CHARACTERIZATION OF THE IN VIVO DEGRADATION PROFILE OF 
TUNABLE POLY(ETHYLENE GLYCOL) HYDROGELS WITH THIO-Β ESTERS 
 
3.1.  Introduction 
Hydrogels are widely used for biomedical applications due to their soft tissue 
properties, high water content, and biocompatibility.43, 44, 47, 213 The versatility and control 
over hydrogel properties make them ideal for a range of scaffold geometries such as bulk 
slabs, microspheres, foams, and 3D-printed constructs.85, 214, 215 Many hydrogels exhibit 
tunable properties that can be modulated chemically, physically, and biologically making 
them ideal for tissue engineering.45-47, 148, 216-218 Degradable hydrogels have been 
increasingly investigated for their use in a variety of applications ranging from drug 
delivery to cell matrices. Control over degradation properties is important to promote 
functional tissue growth, controlled drug release, and controlled cell behavior.50, 219 Slow 
degrading systems have been shown to limit cellular migration, tissue ingrowth, and 
remodeling.62-64 Additionally, non-degradable, woven gauzes used in wound treatment are 
prone to linting fibers and adhering to wound tissue during removal.65 The development 
of hydrolytically degradable wound dressings serve to improve tissue ingrowth and reduce 
inflammatory responses due to residual dressing debris.  
Acrylated and methacrylated poly(ethylene glycol) (PEG) hydrogels have been 
shown to degrade slowly in vivo demonstrating a need for hydrogel scaffolds with 




polymers have been investigated to increase degradation profiles; however, they rely 
solely on cell mediated degradation.50, 221-223 Additionally, increasing hydrolytic 
degradation has investigated through the use of poly(β-amino ester)s (PBAEs). A library 
of linear macromers was synthesized and resulting degradation and mechanical behavior 
was analyzed.66  Studies have shown the ability to tune properties of the PBAEs such as 
degradation rate and modulus through varying concentrations of PEGDA.68 This  use of 
PBAEs to develop a tunable degradation system has been widely characterized for its 
tunable mechanical properties; however, with increasing degradation rate  there was a 
significant effect on gel fraction; thus effecting resulting hydrogel properties such as 
swelling ratio, compressive modulus, and tensile modulus.68-70 Another method to increase 
hydrolytic degradation of PEG hydrogels is the use of thiol-acrylate chemistries. These 
step-growth polymerizations can be tuned using stoichiometric monomer ratios to get 
desired endgroup functionality.62, 71 The reaction occurs when PEG-diacrylate (PEGDA) 
chains react with a dithiol in a Michael-type addition reaction to form water soluble 
PEGDTT polymer chains.72, 73 The increased hydrolytic lability of dithiothreitol (DTT) 
bridges is due to the presence of a thioether bond proximal to the ester bonds present in 
PEGDA.64, 72 The presence of this thioether creates a more positive atomic charge on the 
carbonyl carbon of the ester, enhancing the reactivity of nucleophilic attack which is the 
first step of a base-catalyzed ester hydrolysis.64 This reaction of DTT with PEGDA allows 
for degradation to occur within clinically relevant time scales.73 Bulk properties of the 
hydrogel as well as degradation rate can be tuned through variations in molecular weight 




concentration increases degradation rate, these systems lack the control over matrix 
swelling and modulus which has been shown to play a role in cell-material interactions.224-
227 Another method of that has been investigated to control degradation includes the 
modulation of  ratios of PEGDTT:PEGDA.67 This biodegradable system has been 
investigated for the use of protein release, 3D stem cell culture arrays, and to examine 
ECM cell adhesion on ligand type and concentration.73, 76, 77 Although extensive in vitro 
analysis on mechanical properties and cell compatibility has been completed to 
characterize these hydrogels the in vivo degradation and host response has yet to be 
investigated to demonstrate clinically relevant degradation and cytocompatibility.   
In this study, the in vivo degradation profile of PEGDTT hydrogels were 
investigated to understand the correlation between in vivo and in vitro degradation 
profiles. PEGDA and PEGDTT of similar molecular weights were synthesized and 
swelling ratio was analyzed to demonstrate initial hydrogel properties. Different ratios of 
PEGDTT:PEGDA were investigated to determine degradation profile over 4 weeks. First, 
in vitro degradation profiles in PBS were characterized at 37°C, measuring changes in 
swelling ratio over time until complete dissolution. Samples were also implanted 
subcutaneously using a standard rat model for up to 4 weeks. Swelling ratio and sample 
recovery were used as an indicator of the in vivo degradation over time. Additionally, cell 
attachment of bioactive compositions and cell viability of the degradation products was 
evaluated to determine cytocompatibility and cell-material interactions. Collectively, this 




biodegradable PEG-based hydrogel system to support neotissue formation and reduce 
inflammatory response due to residual wound dressing particulate. 
3.2.  Materials and Methods 
3.2.1.  Materials 
All chemicals were purchased from Sigma Aldrich (Milwaukee, WI) and used as 
received unless otherwise noted. 
3.2.2.  Synthesis of Poly(ethylene glycol) diacrylate (PEGDA) 
PEGDA was synthesized according to a method adapted from Hahn, et al.56 
Briefly, acryloyl chloride was added dropwise to a solution of PEG 2 kDa, 3.4 kDa, 6 kDa, 
or 10 kDa diol and triethylamine (TEA) in dichloromethane (DCM) under nitrogen. The 
molar ratio of PEG, acryloyl chloride, and triethylamine was 1:2:4, respectively. After the 
addition of acryloyl chloride, the reaction was stirred for an additional 24 hours at room 
temperature. The resulting solution was then washed with 8 molar equivalents of 2 M 
potassium bicarbonate to remove acidic byproducts. The product was then precipitated in 
cold diethyl ether, filtered, and dried under vacuum.  
3.2.3.  Synthesis of Poly(ethylene glycol) diacrylate with thio-β esters (PEGDTT) 
PEGDTT was synthesized by adding d,l-dithiolthreitol (DTT) and TEA dropwise 
to a solution of PEGDA (2 kDa or 3.4 kDa) in DCM, Figure 3.1. PEGDTT-L and 
PEGDTT-H were synthesized from PEGDA 2kDa or 3.4 kDa, respectively to develop low 
and high molecular weight macromers. The molar ratio of PEGDA, DTT and 
triethylamine was 3:2:0.9, respectively. After the addition of the DTT and triethylamine, 




precipitated in cold diethyl ether, washed, filtered, dried under ambient conditions for 24 





Figure 3.1. (A) Synthesis of poly(ethylene glycol) diacrylate with ester linkages 





Characterization of PEGDA and PEGDTT was confirmed using proton nuclear 
magnetic resonance (1H-NMR) spectroscopy and gel permeation chromatography (GPC). 
Proton NMR spectra of control and functionalized polymers were recorded on a Mercury 
300 MHz spectrometer using a TMS/solvent signal as an internal reference. Percent 
conversions of PEG diol to acrylate end groups was greater than 85%. Percent acrylation 




(CDCl3): 3.6 ppm (m, -OCH2CH2-), 4.3 ppm (t, -CH2OCO-) 6.1 ppm (dd, -CH=CH2), 5.8 
and 6.4 ppm (dd, -CH=CH2). PEGDTT: 
1H NMR (CDCl3): δ 2.6 ppm (t, -CH2CH2S-), 
2.7 ppm (dd, -SCH2COH-), 2.8 ppm (t, -OCOCH2-), 3.0 ppm (two overlapping s, -
CHOH ), 3.6 ppm (m, -OCH2CH2), 4.2 and 4.3 ppm (t, -CH2OCO-), 6.1 ppm 
(dd, -CH=CH2), 5.8 and 6.4 ppm (dd, -CH=CH2).   
Molecular weights of the PEGDA and PEGDTT macromers were also determined 
with an Agilent Technologies 1260 Infinity II GPC system. Approximately 5 mg 
specimens were dissolved in 0.1 M lithium bromide in dimethylformamide at a 
concentration of 5 mg/mL at room temperature and syringe filtered. Samples were 
prepared just prior to injection into the GPC system to limit degradation of PEGDTT 
samples. Injections of 100 μL of DMF were passed through 2 Phenogel columns with 
molecular weight ranges of 1k – 75k Da at a flow rate of 1.0 mL/min and temperature of 
25ºC. The separated components were passed through an Agilent Multi Detector system 
at 30 ºC, and the molecular weight distribution was determined using the Agilent 
GPC/SEC software using RI detection. Molecular weight averages were reported relative 
to polyethylene glycol standards. Averages were obtained for each polymer by dissolving 
3 separate specimens and running the specimens in duplicate.  
3.2.4.  Hydrogel Swelling Ratio 
Hydrogels of varying composition were fabricated by making (10 wt%) precursor 
solutions in RO water to demonstrate a tunable degradation rate. A photoinitiator solution 
(1 mg Irgacure 2959 per 0.01 ml 70% ethanol) was added at 1 vol% of precursor solution. 




to long wave UV light (Intelli Ray Shuttered UV Flood Light, Integrated Dispensing 
Solutions, Inc., 365 nm, 4 mW/cm2). The compositions varied the concentration of 
PEGDTT and PEGDA (100:0, 85:15, 75:25, and 0:100 wt%) while keeping the total 
polymer fraction constant at 10 wt%. To measure swelling ratio, six 10-mm discs were 
punched from hydrogel sheets. Samples were swollen in PBS for 3 hours to reach 
equilibrium swelling ratio and weighed to determine the equilibrium swelling mass (Ws). 
Then specimens were dried under vacuum overnight to determine dry mass (Wd). The 





3.2.5.  Gel Fraction 
Gel fraction of hydrogel compositions was also evaluated to determine extent of 
network formation of starting macromers and mixed compositions. To measure gel 
fraction, six 10-mm dics were punched from hydrogel sheets after crosslinking and dried 
under vacuum over night to determine dry mass (Wd). The samples were then soaked in 2 
ml of DCM for 24 hours to remove uncrosslinked polymer and dried under vacuum 
overnight. Then specimens were weighed to determine the redried mass (Wrd). The gel 




× 100 [2] 
3.2.6.  Compressive Modulus 
For modulus measurements, 6 specimens (D = 10 mm, T = 1.5 mm) were punched 
from crosslinked sheets and swelled in PBS for 3 hours to reach equilibrium swelling. 




(RSAIII, TA Instruments) equipped with a parallel-plate compression clamp. Testing was 
performed under unconstrained compression at room temperature. The linear viscoelastic 
range was determined for each composition using dynamic strain sweeps. Then a strain 
within the upper end of the linear viscoelastic range was used on a constant strain 
frequency sweep between 0.79 and 79 Hz. The compressive storage modulus was taken at 
1.25 Hz. 
3.2.7.  In Vitro Degradation 
The 10 mm hydrogel discs were also evaluated to determine hydrolytic 
degradation by incubation in 7.4 pH PBS supplemented with 1% Penicillin Streptomycin 
at 37°C for 28 days with biweekly solution changes. The swollen masses were recorded 
at discrete time points for 28 days or until complete dissolution. The swelling ratio (Q) 
was then calculated and used to characterize the network degradation. 
3.2.8.  Human Dermal Fibroblast (hDF) Activity 
All studies were performed with human dermal fibroblasts (hDFs, Gibco) cultured 
in Dulbecco’s Modified Eagle Medium (DMEM; Gibco) supplemented with 10% fetal 
bovine serum (FBS) and 1% Penicillin Streptomycin. All cells were harvested for use at 
passage P2-P4 and seeded at 10,000 cells per well. 
3.2.9.  hDF Viability of Degradation Products 
10 wt% hydrogels of PEGDTT-L and PEGDTT-H and were fabricated and dried 
to obtain 10 mg/ml concentration of polymer in supplemented DMEM. Polymer solutions 
were then incubated at 37C for 1 week until complete dissolution. Solutions were then 




plates and grown for 3 days to reach a confluent monolayer. hDFs were then exposed to 
the degradation products for 24 and 72 hours and viability was analyzed utilizing a 
LIVE/DEAD assay kit (Molecular Probes). Cells were washed with PBS, stained with 2 
µM calcein-AM (live) and 2 µM ethidium homodimer-1 (dead) for 30 minutes at 37°C, 
and washed with PBS for imaging. Imaging (5 images per specimen) was conducted on 
four specimens with a fluorescence microscope (Nikon Eclipse TE2000-S). 
3.2.10. hDF Proliferation 
A Quant-iT™ PicoGreen® dsDNA Assay Kit (Molecular Probes) was utilized to 
quantify cell proliferation and density after exposure to degradation products for 24 and 
72 hours. At selected time points, hDFs were thermally lysed and the assay was performed 
according to manufacturer instructions.  Fluorescence intensity was assessed using a plate 
reader (Tecan Infinite M200Pro) with excitation/emission wavelengths of 480/520 nm, 
respectively. Average cell number was determined by converting dsDNA values to 
individual cell number using 6.9 pg DNA/cell (n = 4 per composition). 
3.2.11. hDF Adhesion and Spreading 
Bioactivity was conferred to the hydrogels by adding 4 mg/ml of 0.1X 
functionalized collagen to hydrogel precursor solutions as previously reported by 
Browning et al.205 Briefly, collagen type I was functionalized with an acrylate-PEG-NHS 
linker (JenKem) to incorporate photoreactive crosslinking sites at a molar ratio of 0.1:1 
(Acr-PEG-NHS:NH2). Cylindrical slabs (D = 10 mm) were punched from PEGDTT-L and 
PEGDTT-H hydrogel compositions and placed into a 48 well plate. Cells were seeded and 




Gibco). hMSCs were washed with PBS, fixed in 3.7% glutaraldehyde, stained for F-actin 
and nuclei with ActinGreen 488 and NucBlue ReadyProbes Reagents (Molecular Probes), 
and imaged via fluorescence microscopy (Nikon Eclipse TE2000-S). Cell adhesion was 
quantified using ImageJ software (n = 4). 
3.2.12. In Vivo Analysis 
All procedures were approved by the Texas A&M University Institutional Animal 
Care and Use Committee. Hydrogel specimens (D = 10 mm, T = 1.5 mm) were obtained 
from the same slabs used in the in vitro degradation studies to ensure consistency between 
studies and sterilized via sterile filtration, electron beam, or ethylene oxide sterilization 
for sterilization studies. The chosen formulations were determined via scouting studies 
with gels fabricated from a range of compositions of PEGDTT:PEGDA to ensure that 
compositions would degrade within the time points of the study and sterilized via ethylene 
oxide sterilization. Three month old female Sprague Dawley rats were anesthetized with 
3% isoflurane, their backs were shaved, and incision sites were scrubbed with povidone-
iodine and isopropyl alcohol. Two 15 mm incisions were made on the dorsal side of the 
rats and blunt dissection was used to prepare implant pockets (2 per side). Specimens were 
introduced through the incision and positioned within the pocket away from the incision 
site. The incisions were then closed with stainless steel surgical staples and were removed 
7 days post-implantation. After 2, 3, 7, 14, and 28 days, rats were euthanized via carbon 
dioxide inhalation with subsequent bilateral thoracotomy performed as a secondary form 




in PBS for 3 hours prior to analysis. Swelling ratio was then measured as described above 
to measure the extent of degradation. 
3.2.13. Statistical Analysis 
All statistical analyses were expressed as the mean ± standard derivation of the 
mean unless stated otherwise. Statistical analysis was performed by a paired two-tailed 
student’s t-test. Statistical analysis for comparison between multiple groups was 
conducted with one-way analysis of variance (ANOVA) with Tukey’s post-hoc analysis. 
Statistical significance was accepted at p < 0.05. 
3.3.  Results and Discussion 
3.3.1.  Hydrogel Characterization 
Macromer synthesis of PEGDA and PEGDTT was confirmed using 1H-NMR, 
Figure 3.2. End-group analysis yielded an average number average molecular weight (Mn) 
of ~6.4 kDa and ~11.1 kDa for PEGDTT-L and PEGDTT-H, respectively. GPC was used 
to further characterize the molecular weight and polydispersity of the resulting macromers, 
Figure 3.3. Although average Mn was similar between PEGDTT-L and PEGDA 6K 
macromers (5220 vs 5590 Da) and PEGDTT-H and PEGDA 10K macromers (8160 vs 
9090 Da), there was a large increase in molecular weight distribution with the synthesized 
PEGDTT macromers. This analysis demonstrated the synthesis of the PEGDTT 
macromers resulted in a heterogeneous population of macromers with molecular weight 
distributions between 1.9-64 kDa and 3.2-57.5 kDa for PEGDTT-L and PEGDTT-H, 
respectively. The observed peak average molecular weight (Mp) values for PEGDTT-L 




A similar trend was also observed in PEGDTT-H with molecular weight values starting at 
3 kDa PEGDA blocks building to molecular weights of 6, 9, and 12 kDa. Maximum Mp 
observed were 64 and 57.5 kDa for PEGDTT-L and PEGDTT-H, respectively. These 
results indicate that there was a portion of the PEGDA macromer that remains unreacted, 
a portion that forms the desired triblock, and a portion that undergoes subsequent coupling 
to form higher molecular weight species. Future work will investigate improved control 
of stoichiometric ratios and reaction times to yield a more homogeneous molecular weight 
macromer. It is hypothesized that the observed variation in molecular weight distribution 
will have an effect on resulting hydrogel mesh size thus affecting material properties.228 
Namely, that the variable chain length will increase the heterogeneity of the network 
structure with localized regions of higher and lower crosslink density. A similar result was 








Figure 3.2. Proton NMR spectra of (A) PEGDTT-L, (B) PEGDTT-H, (C) PEGDA 6K, 





Figure 3.3. GPC chromatagrams of PEGDA 6K (A), PEGDA 10K (B), PEGDTT-L (C), 
and PEGDTT-H (D). Average Mn, Mw, and PDI of each composition (n = 3) are 




Initial gel fraction and swelling ratio of degradable macromers were measured to 
characterize the properties of each macromer, Figure 3.4. Comparable gel fraction was 
observed for all compositions containing PEGDTT-L (~93%), with the PEGDA 6K 
control having a 97% gel fraction. Similarly, comparable gel fraction was observed in the 
PEGDTT-H compositions and the PEGDA 10K (>94%). These high gel fractions 
demonstrate good network formation in the original macromers and with their resulting 
compositions. Following a similar trend, observed swelling ratios for the PEGDTT-L 
compositions were statistically similar between 16.6-17.1, and the PEGDA 6K swelling 
ratio was 15.0. Additionally, PEGDTT-H and PEGDA 10K compositions exhibited 
swelling ratios between 17.7-18.8. Here, we demonstrate the capability of creating 
PEGDTT-based degradable macromers with comparable swelling ratio independent of the 
number of incorporated thio-β esters. Although all PEGDTT-H compositions exhibited 
similar properties to that of the non-degradable PEGDA 10K control, it was observed that 
the PEGDTT-L compositions had slightly different properties to that of the non-
degradable PEGDA 6K control. We hypothesize that slightly different changes in initial 
starting properties can be attributed to initial macromer acrylation and the distribution of 
molecular weight as demonstrated by PDI, Table 3.1. Table 1 summarizes the hydrogel 
physical properties for all initial starting compositions.  
Tables 3.2 and 3.3 summarize the complete property evaluation of all compositions 
of PEGDTT-L and PEGDTT-H (0/100, 60/40, 75/25, 85/15, and 100/0 
PEGDTT/PEGDA), respectively. Compressive moduli for compositions containing 




6K control displayed an average compressive modulus of 355 kPa. Similarly, 
compositions containing PEGDTT-H and its non-degradable PEGDA 10K control 
exhibited statistically similar compressive moduli ranging from 158 to 195 kPa. In 
addition to maintaining hydrogel swelling ratio, these results demonstrate that the number 
of degradable linkages can be modulated while maintaining a relatively constant initial 
matrix modulus. In contrast, other systems that have utilized the introduction of -
thioesters to increase rates of hydrolysis have demonstrated reduction in compressive 










Figure 3.4. Swelling ratio and gel fraction of PEGDTT-L (A) and PEGDTT-H (B) of 
varying PEGDTT/PEGDA compositional ratios (100/0, 85/15, 75/25, 60/40, 0/100). 




Table 3.1. Summary of hydrogel physical properties: swelling ratio, gel fraction, 











PEGDA 6K 15.0 ± 0.3* 97.6 ± 1.5 355.3 ± 46.5 5590 ± 30 1.0 ± 0.1 
PEGDTT-L 16.7 ± 1.0 93.4 ± 0.0 233.2 ± 20.2 5220 ± 190 2.0 ± 0.1 
PEGDA 10K 17.7 ± 0.4 96.6 ± 1.0 240.2 ± 24.8 9090 ± 60 1.0 ± 0.1 






Table 3.2. Summary of hydrogel physical properties of PEGDTT-L with varying 
concentrations of PEGDA 6K (PEGDTT/PEGDA: 100/0, 85/15, 75/25, 60/40, 0/100). 
PEGDTT/PEGDA Swelling Ratio (Q) Gel Fraction (%) 
Compressive 
Modulus (kPa) 
0/100 15.0 ± 0.3* 97.6 ± 1.5* 355.3 ± 46.5* 
60/40 16.6 ± 0.1 93.5 ± 0.9 255.4 ± 30.6 
75/25 16.8 ± 0.4 93.5 ± 1.0 243.1 ± 42.3 
85/15 17.1 ± 0.8 93.0 ± 1.5 232.7 ± 15.8 




Table 3.3. Summary of hydrogel physical properties of PEGDTT-H with varying 
concentrations of PEGDA 10K (PEGDTT/PEGDA: 100/0, 85/15, 75/25, 60/40, 0/100). 
PEGDTT/PEGDA Swelling Ratio (Q) Gel Fraction (%) 
Compressive 
Modulus (kPa) 
0/100 17.7 ± 0.4 96.6 ± 1.0 195.6 ± 44.4 
60/40 17.9 ± 0.2 95.6 ± 1.2 185.2 ± 34.5 
75/25 17.7 ± 1.0 95.0 ± 1.9 175.9 ± 28.0 
85/15 18.4 ± 1.2 94.8 ± 0.7 158.0 ± 7.0 




3.3.2.  In Vitro Degradation 
Swelling ratio was utilized to assess extent of hydrogel degradation due to cleaved 
network groups resulting in reduced crosslink density.216 In vitro degradation of PEGDTT 
hydrogels was investigated in PBS at physiological temperatures to mimic physiologic 
conditions, Figure 3.5. The ratio of PEGDTT:PEGDA was varied to achieve a range of 




not exhibit any significant degradation over the 28-day period. 100% PEGDTT 
compositions demonstrated a loss of mechanical integrity by day 14 for PEGDTT-L and 
day 17 for PEGDTT-H. Compositions containing 75% or less PEGDTT demonstrated 
increased swelling ratio but did not undergo complete dissolution over the 28-day time 
frame. 100 and 85/15 compositions of PEGDTT-H exhibited slower degradation profiles 
with complete dissolution occurring at 14 and 21 days, as compared to 17 and 28 days for 
PEGDTT-L. As expected, a concentration dependent effect was observed with 
compositions with increasing amounts of PEGDTT experiencing more rapid degradation 
than control PEGDA hydrogels, as demonstrated previously.67 Here, we demonstrate the 
modulation of PEGDTT:PEGDA ratio results in a tunable degradation system that exhibits 
complete degradation between 14 and >28 days with minimal effect on initial matrix 
modulus.  
Macromer molecular weight had an unexpected effect on degradation rate with the 
PEGDTT-H of lower crosslink density displaying a similar degradation rate to that of the 
PEGDTT-L. Previously, Metters et al. demonstrated poly(ethylene glycol)-based hydrogel 
swelling ratio and degradation predictions utilizing experimental measurements and 
theoretical models with increased with molecular weights. Additionally, they demonstrate 
that structural imperfections can lower crosslink density and network architecture can 
result in different hydrolysis kinetics.229 Browning et al. has also demonstrated increases 
in accelerated hydrolytic degradation of 10 kDA PEGDA hydrogel compared to 3.4 kDa 
hydrogels due to changes in crosslink density.230 We hypothesize the differences in 




affecting crosslink density and the number of thio-β esters incorporated. Although 
PEGDTT-H had higher initial swelling ratio, it is hypothesized that the increased number 
of thio-β ester linkages (1.5X) in PEGDTT-L compared to PEGDTT-H resulted in more 
rapid hydrolytic degradation. For the PEGDTT-H hydrogels, the total number of thio-β 
ester bonds within the crosslinked network was relatively lower compared to the 
PEGDTT-L. The number of incorporated thio-β ester linkages could be primarily dictating 












Figure 3.5. In vitro hydrolytic degradation profile as monitored by changes in swelling 
ratio of PEGDTT-L (A) and PEGDTT-H (B) with varying PEGDTT/PEGDA 
compositional ratios (100/0, 85/15, 75/25, 60/40, 0/100) over 28 days at 37°C. XDenotes 
complete dissolution, (- - -) dotted lines denote loss of mechanical integrity. 
Corresponding compressive moduli of PEGDTT-L (C) and PEGDTT-H (D) of varying 




3.3.3.  Cellular Interactions 
In vitro cellular viability of hydrogel degradation products was investigated to 
ensure no cytotoxic effects would be observed as a result of hydrogel degradation, Figure 
3.6. As PEGDTT has been used previously as a vehicle for stem cell encapsulation and 
delivery, no negative effects on cytocompatibility were expected.72, 75, 77 Li et al. 




mg/ml in a macromer dilution assay to test cell viability for biodegradable hydrogel 
compositions.231 Based on this reported data, human dermal fibroblast (hDf) viability was 
determined after 24 and 72 hours of exposure to increasing concentrations of PEGDTT-L 
and PEGDTT-H degradation products. Negative effects were not observed as all tested 
concentrations for both PEGDTT macromers exhibited viability greater than 90% after 24 
and 72 hours. Furthermore, cell density quantification confirmed that cells retained their 
ability to proliferate and maintain high cell densities following exposure to degradation 






Figure 3.6. In vitro cellular viability of human dermal fibroblasts seeded onto 
tissue culture polystyrene (TCPS) after 24 and 72 hour exposure to the degradation 
products of PEGDTT-L (A) and PEGDTT-H (B) at 0.1, 1, and 10 mg/ml. In vitro 
cellular density of human dermal fibroblasts seeded onto tissue culture polystyrene 
(TCPS) after 24 and 72 hour exposure to the degradation products of PEGDTT-L (C) 
and PEGDTT-H (D) at 0.1, 1, and 10 mg/ml. (E) Representative images of live cells 





To demonstrate the utility of PEGDTT hydrogels in regenerative medicine, bioactivity 
was conferred to the biodegradable hydrogels by incorporating acrylate-functionalized 
collagen (4 mg/ml). Incorporation of functionalized collagen has been utilized to improve 
cell attachment and activity on hydrogel scaffolds.205 Here, we demonstrate that both 
PEGDTT-Coll scaffolds support high cell attachment and spreading compared to a 
PEGDA 6K-Coll control, Figure 3.7. Cell morphology and adhesion density was found 
to be statistically similar (p > 0.05) for all bioactive hydrogels and the tissue culture 
polystyrene (TCPS) control. PEG-based hydrogels are generally considered bioinert and 
incorporation of bioactive cues into these synthetic hydrogel scaffolds makes them ideal 
for controlled cellular interactions. Acrylation of RGD, collagen, and peptide sequences 
has been utilized to incorporate bioactivity into hydrogel scaffolds through various 
chemistries to target specific cellular interactions.131-133 In addition to biological cues, 
mechanical signals such as substrate stiffness has been shown to influence cell adhesion, 
migration, and differentiation.224, 225, 232, 233 This work demonstrates a biocompatible 
system that can incorporate targeted bioactivity independent of matrix modulus to guide 








Figure 3.7. Representative in vitro 3 hour cellular attachment of human dermal 
fibroblasts seeded onto PGEDA and PEGDTT-collagen hydrogels (4 mg/ml) and tissue 
culture polystyrene (TCPS) Representative images of cells stained with NucBlue 
(nucleus) and ActinGreen (cytoplasm). (B). In vitro cellular density of human dermal 




3.3.4.  In Vivo Degradation  
Prior to implantation, the effect of sterilization method on hydrogel swelling ratio 
and degradation ratio was investigated, Figure 3.8. There were no statistical differences 
(p < 0.05) in swelling ratio or degradation profiles for any of the sterilization techniques 
tested. Subcutaneous rat models were utilized to assess degradation of PEGDTT 
compositions relative to a PEGDA control, Figure 3.9. All compositions containing 
PEGDTT exhibited significant increases in degradation in the in vivo model compared to 
PEGDA controls. 100% PEGDTT compositions exhibited complete dissolution after 2 
days and no residual sample could be collected. 85/15 and 75/25 PEGDTT-L compositions 
exhibited loss of mechanical integrity after three and 14 days, respectively for PEGDTT-
L. Slower degradation profiles were observed for PEGDTT-H with 85/25 compositions 




75/25 PEGDTT-H composition, the swelling ratio was approaching the limit for loss of 
mechanical integrity and likely would have reached complete dissolution shortly after 14 
days. The in vivo trends correlated with the results observed in vitro with varying 
concentrations of PEGDTT/PEGDA. However, significantly faster rates of hydrolysis 
were observed in vivo compared to in vitro profiles. The increased rate of degradation in 
vivo has been seen in other systems and attributed to decreases in local pH due to acidic 
degradation products or contribution of inflammatory cells.234 
 
Figure 3.8. A) Effect of sterilization method on swelling ratio for degradable PEGDTT-








Figure 3.9. In vivo degradation monitored through swelling ratio of PEGDTT-L and 
PEGDTT-H of varying concentrations 85/15 (A), 75/25 (B), 60/40 (C), and 0 (D) 
fabricated with a similar molecular weight PEGDA was investigated before and after 
subcutatenous implantation in a rat model. XDenotes complete dissolution, XDenotes 




3.4.  Conclusions 
This study characterized the degradation profile of a hydrolytically degradable 
hydrogel, PEGDTT, to support its broad utility in biomedical applications. Degradation 
was tuned through the modulation of thio-β esters in the hydrogel composition. Initial 
hydrogel properties such as swelling ratio, compressive modulus, and scaffold gel fraction 
were systematically controlled independent of hydrolytic degradation rate. The in vitro/in 




modulate degradation profiles independent of matrix modulus. Finally, evaluation of the 
cellular response to the degradation products and bioactivity incorporation demonstrated 
high viability and good cell-material interactions. Overall, this work demonstrates the 
versatility of this degradable hydrogel platform for various applications such as stem cell 





CHAPTER IV  
BACTERICIDAL ACTIVITY OF 3D-PRINTED HYDROGEL GAUZE LOADED 
WITH GALLIUM MALTOLATE 
 
4.1.  Introduction 
The natural wound healing response to injury occurs in four different phases: 
hemostasis, inflammation, proliferation and remodeling. In chronic wounds, issues with 
infection, excessive inflammatory responses, biofilm development, and the inability of 
cells to respond appropriately to reparative chemotactic factors prevent the phases of 
wound healing from occurring.149 Chronic wounds have complex colonizing bacteria with 
Staphlococcus aureus being the most prevalent in venous leg ulcers.235 Although extensive 
research on infection control has been done, several debated issues still exist: critical 
wound colonization and the role of biofilm, antimicrobials, and antibiotics.149 Attempts at 
infection control and reduction of inflammatory byproducts have been investigated 
through debridement. This process helps remove necrotic or infected tissue that slows 
down the wound healing process.23 Other protective dressings thought to address infection 
include absorbent dressings, autolytic debridement dressings, and antimicrobial 
dressings.23, 236, 237 There has been a large shift in antimicrobial investigation due to the 
development of antibiotic resistant bacteria.238, 239 Zubair et al. investigated isolated 
bacteria from diabetic foot ulcer patients and found several classes of antibiotics 
susceptible to resistance.240 The increasing development of resistance in several bacteria 




The ability of antimicrobials to be loaded into dressings and delivered topically 
helps reduce negative systemic effects. However, clinically available antimicrobial 
dressings such as iodine and silver have potential for severe negative outcomes. Iodine 
products are commonly used in wound care to reduce bacterial growth as it has been shown 
to prove effective against most micro-organisms and disrupt mature biofilms in vitro.241 
Dressings containing iodine, however; have been contraindicated for patients suffering 
from thyroid disorders, Grave’s disease, and patients who are pregnant or lactating due to 
systemic absorption.160, 161 Silver has been highly investigated as an antimicrobial because 
it has been shown to be effective against a broad range of micro-organisms.151, 152 Silver 
is absorbed by sensitive strains of bacteria impairing cell walls, inhibiting respiration, and 
inactivating bacterial DNA and RNA.153 However, it has been suggested that uncontrolled 
use of silver could result in bacteria developing resistance and reported incidents of 
allergic response has occurred.151, 154 One of the main challenges is the ability to maintain 
high enough concentrations of silver to provide bactericidal effects without the 
development of dose or concentration dependent toxicity.38  
Recently, gallium maltolate (GaM), a novel antimicrobial agent, has been shown 
to prevent bacterial growth and colonization.167-169, 242 GaM is a coordination complex of 
gallium and maltol, which has an octonal:water partition coefficient of 0.41, illustrating 
its solubility in both water and lipids ideal for bacterial uptake.165, 166 GaM has been found 
to significantly reduce the number of colony forming units (CFUs) of several different 
bacteria types often known to cause biofilm formation.167-170 Gallium functions as a ferric 




the iron dependence in bacterial growth.166 The impact of GaM on cellular actions is 
unclear, but gallium has been shown to promote collagen synthesis, cell migration, and 
favorably modulate integrin expression which are all important aspects of wound 
healing.174, 175 As a result, GaM has the potential to serve as an improved antimicrobial 
with reduced side effects and positively improve wound healing.  
The aim of this study was to evaluate the efficacy of a 3D-printed hydrogel loaded 
with GaM on preventing bacterial infection of chronic wounds. Minimum inhibitory and 
bactericidal concentrations of GaM were determined to validate its use as an antimicrobial 
agent. Poly(ethylene glycol)-diacrylate (PEGDA) hydrogels were fabricated via emulsion 
templating and 3D-printed into a hydrogel gauze with hierarchical porosity. The ability to 
control hydrogel properties, emulsion variables, and scaffold geometry will allow for the 
development of a tunable dressing with potential to improve wound moisture balance. 3D-
printed hydrogels were then characterized to determine the effect of this templated 
architecture on hydrogel swelling rate. It has been shown that appropriate fluid balance 
improves wound healing by preventing tissue dehydration and cell death, accelerating 
angiogenesis, increasing the breakdown of dead tissue, and enhancing the interaction of 
growth factors with target cells.59 GaM-loaded hydrogels were characterized using UV-
Vis to determine release profiles at two loading concentrations. Finally, in vivo analysis 
of GaM release, bactericidal effects, wound closure, and host response was evaluated to 
determine its use as an antimicrobial wound dressing. Overall, the goal of this work was 
to investigate GaM and its role in bacterial inhibition and demonstrate its therapeutic 




4.2.  Materials and Methods 
4.2.1.  Materials 
All chemicals were purchased from Sigma Aldrich (Milwaukee, WI) and used as 
received unless otherwise noted. Poly(ethylene glycol)-diacrylate (PEGDA) and lithium 
phenyl-2,4,6 trimethylbenzoylphosphinate (LAP) photoinitiator were synthesized as 
previously demonstrated.56, 243 Trimethylolpropane ethoxylate triacrylate (TMPE, Mn= 
912 Da), light mineral oil, and Kolliphor P188 surfactant was used in ink formulations. 
4.2.2.  Poly(ethylene glycol)-diacrylate Synthesis 
PEGDA was synthesized according to a method adapted from Hahn, et al.56 
Briefly, acryloyl chloride was added dropwise to a solution of PEG 2 kDa, 3.4 kDa, 6 kDa, 
or 10 kDa diol and triethylamine (TEA) in dichloromethane (DCM) under nitrogen. The 
molar ratio of PEG, acryloyl chloride, and triethylamine was 1:2:4, respectively. After the 
addition of acryloyl chloride, the reaction was stirred for an additional 24 hours at room 
temperature. The resulting solution was then washed with 8 molar equivalents of 2 M 
potassium bicarbonate to remove acidic byproducts. The product was then precipitated in 
cold diethyl ether, filtered, and dried under vacuum.  
4.2.3.  Lithium phenyl-2,4,6 trimethylbenzoylphosphinate Synthesis 
Lithium phenyl-2,4,6 trimethylbenzoylphosphinate (LAP) was synthesized 
according to a method adapted from Fairbanks, et al.243 Briefly, dimethyl 
phenylphosphonite was reacted with 2,4,6-trimethylbenzoyl chloride via a Michaelis-
Arbuzov reaction. Equimolar amounts (0.006 mol) of 2,4,6-trimethylbenzoyl chloride was 




nitrogen blanket. The reaction mixture was stirred overnight and then a four-fold excess 
(0.024 mol) of lithium bromide in 2-butanone (6 wt%) was added to the reaction and 
heated to 50°C for 15 minutes. The precipitated solid was then cooled to room 
temperature, filtered via vacuum filtration, and washed 3 times with 2-butanone.  
4.2.4.  Hydrogel Slab Fabrication 
Hydrogels slabs were (D = 8 mm, T = 1.5 mm) fabricated by making (10 wt%) 
precursor solutions of PEG(6K)DA in water. A photoinitiator solution (1 mg Irgacure 
2959 per 0.01 ml 70% ethanol) was added at 1 vol% of precursor solution. Solutions were 
pipetted between 1.5 mm spaced plates and crosslinked by 6 min exposure to long wave 
UV light (Intelli Ray Shuttered UV Flood Light, Integrated Dispensing Solutions, Inc., 
365 nm, 4 mW/cm2). 
4.2.5.  3D-Printed Hydrogel Gauze Fabrication 
Hydrocolloid inks were prepared using a FlackTek SpeedMixer DAC 150 FVZ-K. 
Prior to emulsification, PEGDA and water (25 w/v%) were mixed with Kolliphor P188 
surfactant (10 w/v%), TMPE crosslinker (5 w/v%) and LAP photoinitiator (40% of total 
moles of acrylate groups) in the SpeedMixer cup. Once combined, light mineral oil was 
added to the aqueous, hydrogel solution in four additions and mixed at 2500 rpm for 2.5 
minutes each, until a 75% weight fraction was achieved. Once emulsified a ceramic stir-
bead (10 mm diameter and height) was added and mixed at 3500 rpm for 2.5 minutes in 
the speed mixer.  
3D-printed hydrocolloids were fabricated utilizing a RepRap Prusa i3 with an 




system. Hydrocolloids were loaded into a customized HYREL EMO-25 extruder equipped 
with a luer lock adapter and a 22 gauge blunted stainless steel needle (413 µm, 6.35 mm 
in length, Sigma Aldrich). The extruder was modified to print emulsion inks in a cure on 
dispense manner. Briefly, four 3-watt ultraviolet (UV) LEDs (365 nm, Mouser 
Electronics, Mansfield, TX) were mounted to a heat sink and affixed to the extruder 
syringe, approximately 50 mm above the nozzle tip. The MOSFETs are externally 
powered to accept up to 24 V which allows for precise tuning of the voltage driving the 
UV LED cure source and allowed for UV of 100 mW/cm2. Cylindrical constructs (h = 4 
mm, r = 10 mm) in OpenSCAD program, were exported as an STL file, and then imported 
into the “slicing” software, Slic3r version 1.2.9 with the following printing parameters: 
printing speed of 10 mm/s, nonprinting speed of 25 mm/s, layer thickness of 200 μm, 
rectilinear grid infill of 70%, extrusion width of 0.6 mm, one perimeter, and no top or 
bottom solid layers.  
The removal of the mineral oil from printed constructs was required for accurate 
characterization. The constructs were first allowed to completely air dry to allow for bulk 
oil removal and thorough swelling in DCM. Samples were then soaked in a series of 
washes for 1 hour each in DCM, 50% v/v DCM/ethanol, ethanol, and 50% v/v 
ethanol/water. Finally, constructs were soaked overnight in water. After extraction and 
swelling in water overnight, constructs were frozen at -80°C and lyophilized.  
4.2.6.  Hydrogel Characterization 
To measure swelling ratio, hydrogel slabs were swollen for 3 hours to reach 




were then dried under vacuum overnight to determine dry mass (Wd). 3D-printed 
specimen dry weights (Wd) were measured after cleaning and lyophilizing. Both hydrogel 
specimen types were then submerged in RO water and swollen weight (Ws) weight was 





4.2.7.  Gallium Maltolate Loading 
Hydrogel dressings (D = 10 mm, T = 1.5 mm) were loaded at two concentrations 
of gallium maltolate (Norac, Inc., Azusa, CA, USA): low (~2 mg/dressing) and high (~7 
mg/dressing). To achieve these loading concentrations GaM was dissolved in DCM at 8 
mg/ml and 30 mg/ml to achieve low and high concentrations, respectively. Dried hydrogel 
dressings were measured (Wdi), placed into glass vials, and submerged in 2 mL of GaM 
solutions based on desired concentration. Hydrogels were swelled for 3 hours to reach 
equilibrium swelling to ensure full hydration in GaM solutions. GaM solutions were then 
extracted and air dried for 10 minutes prior to an overnight vacuum dry. Dried hydrogel 





4.2.8.  Gallium Maltolate Release 
GaM release was performed under two conditions to better predict in vivo release, 
submersion and Transwell® models. In the submersion models GaM loaded hydrogels 
were submersed in 2 mL of water and samples were extracted at distinct time points and 




were prehydrated with 80 l of RO water and placed into a 12 mm Transwell® permeable 
membrane insert in a 12 well plate. Wells were filled with 500 l of water to fill up to the 
insert membrane interface. Releasate was collected at distinct time points and water was 
replaced. 
To measure GaM concentrations a Cary 50 UV-Vis spectrophotometer (Agilent 
Technologies) recorded UV-Vis absorption spectra in the range of 200 to 400 nm. The 
data were collected with a scan speed of 300 nm/sec and 0.5 nm resolution. A calibration 
curve was generated for concentrations of GaM in water between 5 and 25 M to create a 
standard curve. Collected GaM releasates were diluted to a theoretical concentration of 
15-20 M with water to prevent saturation. 
4.2.9.  Bacteria and Growth Conditions 
Staphylococcus aureus (S. aureus; ATCC 29213) and methicillin-resistant S. 
aureus (MRSA; ATCC 43300) were cultured in brain heart infusion broth (BHIB; Beckton, 
Dickinson and Company, Sparks, MD, USA) for 24 h at 37 °C on a shaker plate at 
250 rpm. Bacterial cells were pelleted by centrifugation at 3000 × g for 10 min and 
washed 3 times with phosphate-buffered saline (PBS; Thermo Fisher Scientific). The 
concentration of bacteria was determined spectrophotometrically (Smartspec 3000) at an 
optical density (OD) of 625 nm, and approximately 5 × 106 colony forming units (CFU) 
/ml were inoculated into Roswell Park Memorial Institute 1640 Medium (RPMI; Thermo 
Fisher Scientific). All RPMI 1640 media were supplemented with 5 mL sodium pyruvate 
(100 mM, Thermo Fisher Scientific) and 5 ml glutamax solution (200 mM, Thermo Fisher 




effects of GaM on growth of S. aureus and MRSA. In all experiments, concentrations of 
bacteria were determined by 10-fold serial dilutions cultured in triplicate on brain heart 
infusion agar.  
4.2.10. GaM Minimum Inhibitory Concentration 
The MIC of GaM against S. aureus and MRSA was determined by identifying the 
lowest GaM concentration that prevented visible bacteria growth. Gallium maltolate was 
suspended in RPMI at a concentration of 8 mg/ml. All MIC tests were performed using 
96-well plates. All dilutions were 2-fold dilutions starting at 4 mg/ml gallium maltolate 
and ending at 0.25 mg/ml. 3D-printed hydrogels samples loaded with GaM were evaluated 
by submersion of dressings in RPMI to create a final concentration of 8 mg/ml and 
releasate was evaluated at final concentration of 4 mg/ml. Wells containing RPMI medium 
with or without the Staphylococcus isolates were included as positive and negative control 
wells, respectively. Bacterial growth was measured by a change in turbidity of the OD at 
625 nm utilizing a microplate reader (BioTek Synergy 2) at time zero and then at 24 hours 
after incubation at 37C. After 24 hours of GaM exposure, bacterial concentrations were 
determined and reported as CFU/ml.  
4.2.11. In Vivo Splinted Wound Model 
All procedures were approved by the Texas A&M University Institutional Animal 
Care and Use Committee. Two month old C57BL/6 inbred mice were utilized to 
investigate bacterial inhibition and wound healing for a 3D-printed hydrogel dressing 
study. Mice were anesthetized with 3% isoflurane and injected with 0.3 mg/ml 




removed with two applications depilatory cream. The surgical area was then cleaned with 
chlorhexidine and isopropyl alcohol. One 8 mm biopsy punch was taken from the back 
and a silicone ring (10 mm OD and 6 mm ID, 12 mm OD and 10 mm ID) was glued to the 
skin and sutured (Quill Monoderm VLM-1009) for hydrogel slab and 3D-printed hydrogel 
dressing studies, respectively. Mice were inoculated with 30 L of 3.3X104 CFU/ml of S. 
aureus (ATCC 29213) to yield a concentration of 1000 CFU/wound.  
GaM loaded 3D-printed hydrogel dressings (D = 10 mm, T = 1.5 mm) were added 
to the mouse wounds 24 hours after initial inoculation. GaM concentrations (Low – 2 mg 
and High – 7 mg) were chosen based on preliminary in vivo scouting studies and 
therapeutic range of in vitro MIC studies. 3D-printed hydrogel dressings loaded with GaM 
were sterilized via ethylene oxide sterilization. Treatment groups consisted of PBS, low, 
and high GaM loaded dressings. GaM loaded dressings were pre-hydrated with 80 L of 
PBS prior to application and re-bandaging. Wounds were then bandaged with OpSite 
Flexifix bandages. Bandages and wound dressings were changed at 24 hours after initial 
application and then every 2 days for 12 days. At each time point bandages were removed, 
fresh dressings were applied, and animal weight was obtained according to AUP. 
To quantify the in vivo GaM release, hydrogel dressings were collected at 48 hours 
post application and the GaM content remaining in the dressing was quantified using mass 
spectrometry as compared to the initial concentration in dressings. Briefly, GaM-loaded 
specimens (0 hour) were digested with nitric acid, hydrochloric acid, and hydrogen 
peroxide in a Milestone UltraWave microwave digester and then analyzed for GaM using 




specimens were reported as an average of quantified GaM mass. Hydrogel dressings (n=6) 
were removed from the wound after 48 hours and soaked in 70% ethanol. The liquid 
samples were then diluted with 1% nitric acid and the samples analyzed for GaM on a 
Perkin Elmer DRC 2 ICP-MS instrument. The GaM remaining in the dressing was 
reported as an average of GaM mass. 
After 12 days, mice were euthanized, bandages and rings were carefully removed, 
and wound size was measured. Wounds were excised with 12 mm biopsy punches and 
split for analysis of bacterial growth and histology. Tissue excised for bacterial growth 
analysis was homogenized in 5 mL of PBS using a tissue homogenizer and diluted in PBS 
1X102, 1x103, and 1X104-fold. 100 L of diluted samples were plated in luria broth (LB) 
agar plates and incubated at 37C for 24 hours. Colonies were then counted to determine 
CFU/g of tissue. Tissues were processed for routine paraffin embedding, sectioned with a 
microtome (5 um-thick sections) and stained with hematoxylin and eosin (H&E). Samples 








Debris, Inflammatory Cells, Epithelial 
Hyperplasia, Vascular Buds 
Bacteria, 
Foreign Material 
0 0-10% None No 
1 10-25% Mild Yes 
2 25-50% Moderate  








4.2.12. Statistical Analysis 
All statistical analyses were expressed as the mean ± standard deviation unless 
stated as standard error of the mean (SEM). Statistical analysis was performed utilizing a 
standard one-way ANOVA with Tukey’s post-hoc analysis for multiple comparisons with 
variables greater than two. Statistical significance was accepted at p < 0.05 with a 95% 
confidence interval. 
4.3.  Results and Discussion 
4.3.1.  Hydrogel Characterization 
Approaches to developing hydrogel inks with rheological properties suitable for 
3D-printing has been investigated to improve print fidelity by incorporating additives to 
increase viscosity.244, 245 Here, we demonstrate the ability to 3D-print a hydrogel 
hydrocolloid ink photocrosslinked via UV irradiation through a Cure-on-Dispense 
method, Figure 4.1A. Typical bulk hydrogel slabs are limited to scaffold geometries that 
can be cast into a mold. This oil-in-water emulsion exhibits viscosities for high fidelity 
printing and creates a dual porosity dressing with both macro- and micro-pores. 
Microporosity is formed upon the removal of the oil phase which can be tuned through 
emulsion parameters while the macroporosity is formed through 3D-printing, Figure 
4.1B. The dual porosity of this 3D-printed construct allows for rapid water uptake reaching 
equilibrium swelling after 15 minutes compared to a hydrogel slab at 3 hours, Figure 
4.1C. Additionally, the rapid swelling capabilities of these 3D-printed hydrogel dressings 
have potential for therapeutic delivery of an antimicrobial agent to create a multifaceted 




printed hydrogel dressings compared to traditional hydrogel slabs. However, both systems 
achieve near complete release after 24 hours. We identified that the accelerated swelling 
capacity of the 3D-printed dressing allows for rapid release that could reach the 





Figure 4.1. (A) Schematic representation of 3D-printed hydrocolloid inks via extrusion 
deposition printing with cure-on-dispense technology. (B) Comparison of dimensional 
changes upon hydration and dressing porosity of 3D-printed hydrogel. (C) Swelling ratio 
characterized over time to investigate swelling rate improvements of 3D-printed 










4.3.2.  In Vitro Bacterial Inhbition Analysis 
Bacterial inhibition studies were performed to identify therapeutic ranges of 
soluble GaM for both S. aureus and MRSA. The minimum inhibitory concentrations 
(MIC) of S. aureus and MRSA were found to be 2 mg/ml and 1 mg/ml, respectively, 
Figure 4.2A. These reported concentrations had no visible growth of bacteria after 24 
hours compared to the negative control. GaM MICs for S. aureus and MRSA were 
consistent with those reported previously by Baldoni et al.169 Optical density (OD) was 
utilized to determine statistical changes in bacterial growth and confirmed the visual MIC 
assay. To quantify bacterial growth after 24 hour exposure to GaM, colony forming units 
(CFU) for a single concentration below the MIC and up to 4 mg/ml were counted for both 
S. aureus and MRSA. A concentration dose dependence was demonstrated by reduction 
in CFU/ml as demonstrated in Figure 4.2B. Concentrations below the MIC for both S. 
aureus and MRSA resulted in a significantly increased bacteria colony counts of ~5.3 x10 
and 9.4 x104 CFU/ml, respectively. Although these concentrations do not illustrate a 
bactericidal effect, MICs are the gold standard for determining microbe susceptibility.246 
Additionally, it has been shown that concentrations of bacteria less than 105 CFU/g tissue 
allowed for wound healing to proceed normally.247 These results demonstrate the utility 
of GaM in reducing bacteria activity with potential to inhibit bacterial load in vivo at 








Figure 4.2. (A) Determination of minimum inhibitory concentration for gallium 
maltolate in MRSA and S. aureus. Minimum inhibitory concentration identified at 1 
mg/ml and 2 mg/ml for MRSA and S. aureus, respectively. *indicates statistical 
differences with respect to negative control. (p < 0.05) (B) Bacterial colony growth after 
24 hour exposure to GaM at concentrations at and above at the MIC. *indicates 
statistical differences with respect to positive control (p < 0.05). 
 
 
4.3.3.  Gallium Maltolate Loading and Release 
Concentrations of GaM between 5 and 25 µM were measured utilizing UV-Vis 
spectroscopy to create a calibration curve, Figure 4.3A. A standard curve was then 
identified utilizing a linear trend line and unknown sample masses were then extrapolated, 
Figure 4.3B and 4.3C. GaM loaded dressings were identified as low GaM and high GaM 
with loaded GaM amounts quantified at 1.4 ± 0.4 mg and 7.05 ± 0.7 mg, respectively. 
GaM loaded dressings were fabricated with a low GaM (1.4 ± 0.4 mg) and a high GaM 
(7.05 ± 0.7 mg) concentration.  In vitro release profiles of GaM from the dressings was 
investigated using two distinct release conditions, sink and diffusion methods, Figure 
4.4A and 4.4B. First, a commonly utilized submersion method was investigated to create 
sink conditions to determine release rates. As expected, submersion release profiles 
demonstrated a burst release of greater than 95% after 1 hour, with concentrations below 
MICs after this time point, Figure 4.4C and 4.4E. Next, a diffusion release method was 




allowing diffusion of through a polyester insert membrane with 0.4 µm pores. Solutions 
were collected over 24 hours to approximate antimicrobial release from the tissue 
contacting surface of the dressing. High burst release, greater than 65%, was observed 
after 1 hour for both concentrations, Figure 4.4D and 4.4F. However, release 
concentrations were greater than the minimum inhibitory concentration for high GaM 
concentrations observed after 1 hour for S. aureus and 2 hours for MRSA. There was a 
minimal concentration dependent effect observed with low GaM loaded dressings, as they 
retained similar release profiles over the 24 hours. However, at this loading concentration, 
only the initial 1-hour time point resulted in concentrations meeting the MIC therapeutic 





Figure 4.3. Gallium maltolate (GaM) concentration (A) calibration curve and resulting 
(B) standard curve at 217 nm. (C) Confirmation of theoretical loading via gravimetrical 








Figure 4.4. GaM hydrogel release schematic for 3D-printed hydrogel dressings in (A) 
Transwell® and (B) submersion model. In vitro GaM hydrogel release profiles from 3D-




To ensure that the GaM retained antimicrobial activity after loading into 3D-
printed hydrogels, a modified MIC assay was performed to investigate bacterial growth in 
the presence of hydrogel releasates, Figure 4.5B. GaM was released from 3D-printed 
dressings by submersion in supplemented RPMI media at a concentration of 4 mg/ml, 




that bacteria growth was inhibited after 24 hours with densities matching negative 
controls. This demonstrated that GaM could be loaded into hydrogel dressings without 





Figure 4.5. (A) GaM loaded hydrogel dressings with increasing GaM concentration. (B) 
Effect of GaM released from antimicrobial-loaded hydrogels on bacterial growth 











4.3.4.  In Vivo Splinted Wound Analysis 
Splinted wound models were then investigated in a murine model to determine the 
effects of hydrogel dressing application on bacterial load and wound closure, Figure 4.6A. 
The addition of a wound dressing creates a barrier and helps reduce infection by 
mimicking the skin’s primary structure.39, 248 Additionally, the incorporation of GaM into 
3D-printed gauze was applied to improve wound moisture balance while inhibiting 
bacterial growth. Dressing changes were performed every 48 hours to ensure GaM 
concentration was in the therapeutic range based on burst release profiles identified in in 
vitro studies.  Mass spectrometry was performed to quantify initial (0 hour) and remaining 
(48 hour) GaM concentration in the dressings after initial application. Initial loading of 
GaM concentrations were determined to be 1597.7 ± 61.5 µg and 5089.4 ± 952.3 µg for 
the low and high GaM loaded dressings, respectively. Less than 3% of GaM remained 
after 48 hours with 6.3 ± 4.1 µg and 148.9 ± 116.2 µg remaining in the low and high 
dressings, respectively. Based on these findings, dressing changes were performed every 
48 hours to ensure complete release and a therapeutic delivery for a total of 12 days. The 
use of these dressings as a carrier for GaM release resulted in significantly decreased 
bacterial growth, ~2x106 CFU/g tissue compared to PBS treated controls, ~50x106 CFU/g 
tissue, Figure 4.6B. There was no significant difference in wound closure of the untreated 
control and wounds treated with the GaM-loaded dressings with approximately 30% 
wound closure after 12 days, Figure 4.6C. Histological analysis determined no significant 
differences (p > 0.05) between the two GaM doses and the untreated control in terms of 




characterization further supports wound dimensional analysis. Additionally, foreign 
material and debris at the wound site had no significant differences illustrating that there 
was no significant dressing left within the wound between dressing applications. 
Inflammatory responses identified for all compositions demonstrated on average between 
mild and moderate inflammatory cell accumulation and similar levels of vascular budding 
demonstrating comparable effects with all treatment types. Collectively, these findings 
indicate that GaM delivery resulted in reduced bacteria growth with no negative effects 









Figure 4.6. (A) Splinted murine wound model schematic with untreated control and 
applied 3D-printed dressing. Data represented as average ± SEM. B) In vivo bacterial 
inhibition determined by CFU/g of tissue for low and high GaM loaded hydrogel 
dressings. *indicates statistical differences between corresponding samples (p < 0.05). 
C) Wound closure assessment of all treatment groups at day 0 and day 12. D) Ordinal 






Current wound therapies aim to prevent wound recurrence and treatment failure 
through compression, infection maintenance, debridement, and appropriate dressing 
selection. Unfortunately, these therapies are often only able to control a single factor and 
inadequately fail to address the complex wound environment. We aimed to develop an 
improved wound dressing that demonstrates both wound moisture balance and infection 
control. Maintaining a moist wound environment has been shown to facilitate the wound 
healing process by preventing tissue dehydration and cell death, enhanced angiogenesis, 
improved breakdown of nectrotic tissue and fibrin, and initiating the interaction of 
chemotactic factors with target cells.59 Clinically applied hydrogel dressings such as 
Granugel® and Aquaform®, have been shown to absorb 23-27% in highly exudative 
wounds but only allow for a marginal 3-5% hydration donation.60 The increased water 
uptake and rapid swelling of our 3D-printed dressings demonstrate their ability to 
influence moisture balance in the wound environment to be applied dry for absorption 
control or applied hydrated for hydration donation. 
 Identifying predictive in vitro methods for transdermal release is important for 
evaluation of compound efficacy and safety. Currently utilized systems range in 
complexity ranging from diffusion cell models, organ-on-a-chip, and in vitro skin 
models.249-252 Ng et al. demonstrates variability in a static franz diffusion cell system due 
to membrane barrier, sampling volume, sampling frequency, and sampling frequency.253 
Additionally, there has been extensive research investigating ex vivo animal and human 
models, however; several limitations exist due to ethical concerns, hair density, and 




human skin cells has been shown to mimic the fibrous extracellular matrix and be utilized 
as a model for full-thickness human skin.254 Here, we utilize two release systems, 
submersion and Transwell®, to demonstrate the release of GaM from our hydrogel 
dressings. The low level sustained release demonstrated with the Transwell® system has 
potential for improved patient comfort and wound care. GaM has been shown that at low 
doses it can provide nearly complete pain relief with topical applications reducing 
inflammation.172, 173 Additionally, gallium has been shown to promote collagen synthesis 
and cell migration that could be beneficial for improved wound closure and healing.174, 175 
We hypothesize that the demonstrated low level release has potential to improve in vivo 
wound healing response.  
In chronic wounds, issues with infection with biofilm development, excessive 
inflammatory responses, and the inability of cells to respond appropriately to reparative 
chemotactic factors prevent the phases of wound healing from occurring.149 Chronic 
wounds have complex colonizing bacteria with Staphlococcus aureus (S. aureus) being 
the most prevalent in venous leg ulcers.235 In the late 1970s and early 1980s, the emergence 
of methicillin-resistant Staphlococcus aureus (MRSA) became an endemic in the United 
States.255 This strain of S. aureus is resistant to all β-lactam antibiotics demonstrating the 
complications with traditional antibiotic therapies.256   Antimicrobial resistance is rapidly 
developing issue which could result in increased patient outcomes of morbidity and 
mortality.257 Gallium has the potential to overcome typical resistance mechanisms 
associated with antibiotics such as decreased cellular uptake due to permeability of the 




inability for Ga(III) to be reduced like Fe(III), interrupts the reduction and oxidation 
processes necessary for DNA and protein synthesis necessary for  bacterial and 
mammalian cell proliferation.173, 259, 260 Additionally, delivery of antimicrobials locally is 
the preferred delivery method to reduce systemic toxicity, increase efficacy, and to 
overcome problems associated with poor blood circulation in lower extremities commonly 
afflicting patients suffering from diabetes.23 These studies demonstrate the a method to 
deliver GaM to target lower extremity chronic wounds to improve infection control and 
reduce complications with bacterial resistance. 
The in vivo evaluation of GaM demonstrates improved infection control and 
comparable wound closure rates to that of the untreated control. Boateng et al. reports that 
foreign bodies introduced into the wound can cause chronic inflammatory responses and 
lead to wound healing complications.23 Histological analysis of the wound site illustrates 
comparable wound healing in all treatment groups which demonstrates a reduction in 
foreign bodies during dressing changes. Additionally, our dressing design allows control 
over hydrogel chemistry to tailor the design to meet application specific needs. The use of 
a biodegradable hydrogel matrix would eliminate the concerns of residual foreign bodies 
within the wound bed during dressing changes. Concentrations of GaM selected were 
shown to be within the therapeutic range for bacterial inhibition in vitro and complete 
release was confirmed in vivo. Selected concentrations of GaM verified bacterial 
inhibition without off target effects that could negatively affect wound closure. In some 
studies, gallium-based compounds are utilized as anticancer treatments to induce 




in similar wound closure.165, 172, 261, 262 The incorporation of GaM into this 3D-printed 
wound dressing provides an improved delivery method to topically deliver this 
antimicrobial agent to inhibit bacterial growth. These studies demonstrate the potential of 
therapeutic delivery of GaM from a self-tuning moisture balanced wound dressing. 
Current studies are investigating a method to sustain delivery of GaM within the 
therapeutic range to improve long term bacterial inhibition.  
4.4.  Conclusions 
The aim of this study was to develop an improved wound dressing platform 
through incorporation of the novel antimicrobial agent, gallium maltolate, in a 3D-printed 
hydrogel gauze. The multi-layer porosity of this 3D-printed hydrogel dressing allowed for 
controlled moisture balance through rapid water uptake. Antimicrobial activity of GaM 
was characterized by identifying minimum bactericidal concentrations in Staphylococcus 
aureus and Methicillin-resistant Staphylococcus aureus. Release profiles of GaM loaded 
3D-printed hydrogel dressings were identified using submersion and Transwell® release 
systems and retention of antimicrobial activity post release was confirmed. Additionally, 
the effects of GaM loaded hydrogel dressings on wound healing and antimicrobial activity 
were investigated in vivo using a murine splinted wound model. Mass spectrometry 
analysis was utilized to confirm complete delivery of therapeutic dosages were delivered 
prior to dressing change. Explanted wound tissue confirmed decreased bacteria levels and 
wound closure retention with the addition of the GaM loaded dressing. Overall, this work 
provides a versatile platform that can be used to provide a wound dressing matrix to 







5.1.  Summary 
This work establishes several tunable platforms for the development of a 
poly(ethylene glycol)-based hydrogel wound dressing platform. These studies 
demonstrate the fabrication of hydrogel scaffolds with tunable moisture balance, the 
development of engineered proteins for integrin-mediated bioactivity, tunable 
biodegradation for an improved wound dressing, and the incorporation of an antimicrobial 
agent for bacterial inhibition. Collectively, the advancements made in this work aim to 
provide a platform for an improved wound dressing with tunable properties to address 
different wound environments. 
Hydrogel microspheres were developed as a tunable, degradable hydrogel wound 
dressing for improved injectable delivery. These uniform hydrogel microspheres were 
fabricated using a dual fluidics setup to allow for an injectable, space filling dressing for 
irregular shaped wounds. Furthermore, additional fabrication techniques were 
investigated to improve scale-up and throughput. Additionally, a collagen mimetic, 
eColGFPGER was developed to improve protein stability by increasing melting temperature 
while maintaining triple helix formation compared to Scl2GFPGER. Furthermore, steric 
hindrance of integrin binding sites were assessed by monitoring α1 I-domain binding and 




To establish a resorbable hydrogel system to be used in wound dressings, the in 
vitro and in vivo biocompatibility and biodegradation of a PEG-based hydrogel with thio-
-esters was evaluated. Two different PEGDTT macromers were synthesized to achieve 
different hydrogel properties and examine the effect on the degradation profiles. PEGDTT 
macromers (PEGDTT-L and PEGDTT-H) and PEGDA controls were evaluated to 
confirm synthesis, functionalization, and molecular weights. Hydrogels fabricated with 
various ratios of PEGDTT:PEGDA (100:0, 85:15, 75:25, 60:40, and 0:100) were 
investigated to determine the effect of composition on swelling ratio, gel fraction, 
compressive modulus, and degradation profiles. The in vitro biocompatibility of human 
dermal fibroblasts (hDFs) exposed to the degradation products of 100% PEGDTT 
hydrogels exhibited high viability and no effect on cell proliferation after 24 and 72 hour 
exposure. Additionally, bioactivity was conferred into hydrogels and resulting cellular 
attachment and spreading were found to be similar in PEGDTT and PEGDA hydrogels. 
Finally, the in vivo degradation profile was established and PEGDTT compositions were 
found to degrade much more rapidly in vivo compared to the in vitro conditions.  
Finally, the last chapter demonstrates the versatility of this hydrogel system with 
the fabrication of a 3D-printed hydrogel gauze loaded with gallium maltolate (GaM) as a 
wound dressing. The minimum inhibitory concentration (MIC) of GaM was identified in 
Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus demonstrating 
the potential of GaM to inhibit bacterial growth. Development of this 3D-printed hydrogel 
exhibited rapid water uptake demonstrating its capability to be utilized as an antimicrobial 




were identified using Transwell® and submersion release systems over 24 hours. Mass 
spec analysis was utilized to confirm the full release after 48 hours in a murine model. 
Additionally, released GaM from hydrogel dressings was investigated in a modified MIC 
assay and exhibited bacterial inhibition similar to soluble GaM. These GaM loaded 
hydrogel dressings were evaluated in a murine splinted wound model and demonstrated 
decreased bacterial load while maintaining comparable wound closure.  
In summary, this work highlights the potential of this biodegradable hydrogel 
system to serve as an improved dressing to increase wound healing through bioactivity 
incorporation, wound moisture balance, and conferred antimicrobial activity. The 
development of these technologies have not only created a tunable platform for wound 
healing scaffolds but also can be applied to various regenerative applications.   
5.2.  Significance of Work 
There have been several advances in wound healing to improve healing capability, 
reduce amputations, and improve patient comfort and care. Recent wound dressing 
research has focused on scaffold design, vascularization, regulatory factors, and accurate 
in vitro models.  Ideally wound dressings would initiate and manage wound healing in the 
following three ways: manage infection and wound fluid maintenance, encourage cellular 
interactions to promote healthy tissue formation, and degrade at an appropriate rate. 
Specifically, this work investigates a biodegradable hydrogel system to address the 
different aspects of wound healing. The combined technologies discussed in this work 
provides a foundation for the development of a tunable wound healing platform with 




In Chapter 2, a collagen-mimetic injectable hydrogel microsphere wound dressing 
was investigated to space fill irregularly shaped wounds. The hydrogel microsphere 
platform improves upon current hydrogel geometries illustrating its ability to provide 
maximum dermal contact through sphere packing. Controlled modulation of cellular 
interactions through recombinantly expressed Scl2 proteins was further optimized by 
improving protein stability to develop eColGFPGER. Additionally, the tethering of the 
protein into the hydrogel matrix is facilitated through the use of PEG linkers that 
functionalize this protein utilizing amine-NHS chemistries. Modification of this Scl2 
protein also resulted in a reduction of lysines in the protein backbone, and despite the 
steric hindrance from PEG-linkers this engineered design allows for improved cellular 
interactions with integrin binding sites. The ability to modify stability and integrin 
interactions of these Scl2 proteins illustrates an important advantage over traditional 
bioactive factors. As a result of these protein modifications, the incorporation of these Scl2 
proteins into bioinert PEG-based hydrogels imparts bioactivity to provide potential for 
integrin-mediated cellular interactions and wound healing. Through the development of 
the scaffold design, moisture balance, and bioactivity incorporation this dressing has 
potential as a neotissue matrix to promote active wound healing.  
In Chapter 3, the in vivo degradation profiles and biocompatibility of the 
hydrolytically degradable macromer, PEGDTT, was evaluated to support its use as a 
degradable matrix to support wound healing. Poly(ethylene glycol) hydrogels are widely 
used due to their ability to be easily modulated chemically, mechanically, and biologically; 




relevant applications. Although there has been successful modulation of PEG-based 
hydrogels utilizing other chemical modifications, these hydrogels cannot tune degradation 
rate independent of swelling ratio and modulus. By modulating the number of thio-β esters 
in the hydrogel composition, this platform displayed broadly tunable hydrolytic 
degradation while maintaining relatively constant hydrogel swelling ratio and modulus. 
Furthermore, to date there has been limited characterization of the in vivo degradation 
profile of these thio-β ester containing PEG hydrogels. The in vitro-in vivo degradation 
correlation was established and a tunable system was identified to modulate degradation 
profiles independent of matrix modulus. Finally, evaluation of the cellular response to the 
degradation products, in vivo host response, and bioactivity incorporation demonstrates 
the versatility of this platform for various applications and scaffold geometries such as 
stem cell carriers and fabrication of microspheres and 3D-printed dressings for wound 
healing.  
In Chapter 4, antimicrobial loading and release from 3D-printed hydrogels was 
explored to investigate bacterial inhibition in contaminated wounds. This work, 
demonstrated the use of solid freeform fabrication to 3D-print hydrogel gauze with micro- 
and macro- porosity. The fabrication of this dual porosity scaffold led to rapid swelling 
rates and significant water uptake demonstrating its ability to provide improved wound 
fluid balance over traditional bulk hydrogels. The design of this dressing allows for dry or 
hydrated application illustrating its versatility to be used in different wound environments 
to absorb fluids in highly exudative wounds or provide moisture to dry necrotic tissues. 




concentrations for GaM by investigating bacteria optical density, confirming results from 
traditional MIC assays. Dressing compositions were modulated at two doses to investigate 
dose dependence of GaM within the therapeutic range for bacterial inhibition. 
Furthermore, these studies investigated in vivo bacterial inhibition with the addition of 
GaM and demonstrated no inhibition of wound closure with the application of this 
hydrogel gauze. Although GaM has been investigated as a novel antimicrobial agent, these 
studies demonstrate for the first time its incorporation into a wound dressing for 
therapeutic applications and its response in vivo. 
Overall, the methods developed in this work detail a tunable, biodegradable 
hydrogel wound dressing platform with improved regenerative capacity thorough wound 
fluid balance, bacterial inhibition, and bioactivity development. Methods to control 
scaffold geometries were investigated to develop a system that will provide wound 
dressings with control over wound fluid balance. Furthermore, the incorporation Scl2 
proteins and gallium maltolate provide biological cues for improved cellular interactions 
and bacterial resistance, respectively. Cumulatively, each component of this wound 
healing platform provides explicit advantages for improved wound healing but 
independently these tunable systems can be utilized broadly for the development of 
technologies for various regenerative therapies. 
5.3.  Challenges and Future Directions 
Detailed in this work is the development of a hydrogel wound dressing platform 
with tunable properties and imparted antimicrobial activity. Although we have 




investigation must be done to ensure that the incorporation of bioactivity into the various 
scaffold constructs promotes active wound closure and healing. Additionally, further work 
must investigate the combinatorial effect of the incorporation of both bioactivity and 
antimicrobial incorporation to assess the independent and synergistic effects in vivo. 
A primary focus of this work has been incorporating gallium maltolate (GaM) into 
our hydrogel platform to impart antimicrobial activity. Despite having demonstrated its 
minimum bactericidal concentration in vitro and exhibiting release within the therapeutic 
range there is still significant bacterial load observed in vivo. It has been noted in literature 
that there is a bacterial threshold (>105 CFU/g tissue) for wound infection which prevents 
normal wound healing.247 To improve upon bacterial inhibition seen in vivo the 
development of a controlled release system of GaM such as PLGA microspheres could be 
utilized allow for sustained release within the therapeutic concentration range. Here, 
electrosprayed microspheres could be fabricated and release can be tuned through 
fabrication techniques or polymer composition. Fabrication parameters such as polymer 
concentration, solvent, and voltage are a few ways that microsphere size can be 
modulated.263, 264 Smaller particles would provide a larger surface area to volume ratio 
which would correlate to faster release. In addition, release from these microspheres could 
be further tuned by modulating co-polymer concentrations of PLGA as widely 
demonstrated in literature.265-268 Additionally, negative side effects were observed in vivo 
for dressings containing higher concentrations of GaM due to the high burst release. 




microspheres has potential to overcome this limitation. Future studies investigating 
sustained release would need to balance GaM toxicity with therapeutic efficacy.  
Development of a degradable polymer matrix for wound healing is one of the key 
requirements necessary for eliminating negative side effects, such as inflammation, due to 
residual dressing material left in the wound bed. We established a step-growth 
polymerization that tuned stoichiometric macromer ratios to get desired endgroup 
functionality. However; after further investigation of PEGDTT synthesis, it was 
discovered that there was a large distribution of heterogenous molecular weight species. 
Currently, we are investigating a two-step synthesis protocol to have improved control 
over stoichiometry and reaction products to develop monodisperse macromers. By 
controlling molecular weight through macromer synthesis we can better predict hydrogel 
degradation profiles and develop a tunable library of degradable PEGDTT macromers. 
This system has potential for use in several tissue engineering and regenerative medicine 
applications. The development of a library of tunable degradation profiles with various 
hydrogel properties (modulus and swelling ratio) could have a tremendous impact on the 
field. Additionally, preliminary work focused on the investigation of a simulated body 
fluid to predict in vivo degradation profiles in chronic wound environments. Initially, 
PEGDTT hydrogels degraded rapidly in this simulated body fluid and it was hypothesized 
that this solution over predicted in vivo degradation profiles. After comparison of the in 
vitro and in vivo degradation profiles it was noted that PBS did not accurately predict the 
in vitro degradation. Further investigation could be done to develop in vitro degradation 




The incorporation of bioactivity utilizing Scl2 proteins has been investigated for 
their role in integrin mediated wound healing. We have established the tunability of these 
proteins to improve protein stability and modulate cell-material interactions. Through the 
development of this work, we observed batch variability due to production and isolation 
processes during protein expression. Current work being investigated includes protein 
monomer content, aggregation, protein stability, and cellular interactions. After 
confirmation of batch reproducibility, investigation of soluble protein loading and release 
from hydrogel scaffolds will be analyzed. In vitro assays such as CBQCA and BCA can 
be utilized to determine release rates and concentrations necessary for improved cellular 
interactions. Additionally, cell attachment, spreading, and proliferation on bioactive 
hydrogels of all geometries will then be assessed compared to a collagen control to assess 
cell-material interactions. Finally, murine and equine models could be used to evaluate 
this composite scaffold in vivo. Here, the evaluation of integrin binding utilizing histology 
and immunohistochemistry to evaluate wound vascularity, inflammatory cell infiltration, 
and granulation tissue formation could identify the integrin mediated effects. Investigation 
of the wound healing mechanisms due to Scl2 proteins can be utilized through 
investigation of wound cellular composition and wound transcriptional profile using flow 
cytometry and RNA-seq. 
Lastly, each of these platforms have been established independently; however, in 
order to develop a functional wound dressing all of these components must be developed 
into a composite dressing and evaluated collectively. In addition to its antimicrobial 




migration, and favorably modulate integrin expression. The potential synergistic effect of 
GaM with Scl2 could not only allow for antimicrobial incorporation but also improve the 
active wound healing process by improving cellular interactions and resulting collagen 
synthesis. Equine distal wound models can be utilized to evaluate effect of integrin 
contribution and GaM contribution independently and synergistically to evaluate wound 
healing. Additionally, characterization of wound vascularity and inflammatory cell 
infiltration can be investigated through histological analysis. Finally, the incorporation of 
both an antimicrobial agent along with a bioactive protein serves to establish a novel 
biomaterial platform with multifaceted techniques for improved wound healing with 
bacterial inhibition. 
Although additional studies and investigation is necessary to develop a 
combinatorial wound dressing for improved wound healing, the platforms established in 
this work illustrate independently, the ability to address the complex wound environment. 
First, a stable protein with improved cellular interactions to impart bioactivity with 
potential to improve cell-mediated wound closure was developed. Then a biodegradable 
hydrogel system that can be fabricated into various scaffold geometries to modulate 
wound fluid balance was established. Finally, gallium maltolate was incorporated into 
these hydrogel dressings and the antimicrobial properties in splinted wound models were 
demonstrated. In summary, this work provides technologies for improving wound healing 
through wound fluid maintenance, imparted bioactivity and antimicrobial activity, and 
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